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Abstract
Our knowledge of complex pathological mechanisms underlying organ fibrosis is predominantly derived from animal studies. 
However, relevance of animal models for human disease is limited; therefore, an ex vivo model of human precision-cut tissue 
slices (PCTS) might become an indispensable tool in fibrosis research and drug development by bridging the animal–human 
translational gap. This study, presented as two parts, provides comprehensive characterization of the dynamic transcriptional 
changes in PCTS during culture by RNA sequencing. Part I investigates the differences in culture-induced responses in 
murine and human PCTS derived from healthy liver, kidney and gut. Part II delineates the molecular processes in cultured 
human PCTS generated from diseased liver, kidney and ileum. We demonstrated that culture was associated with extensive 
transcriptional changes and impacted PCTS in a universal way across the organs and two species by triggering an inflamma-
tory response and fibrosis-related extracellular matrix (ECM) remodelling. All PCTS shared mRNA upregulation of IL-11 
and ECM-degrading enzymes MMP3 and MMP10. Slice preparation and culturing activated numerous pathways across all 
PCTS, especially those involved in inflammation (IL-6, IL-8 and HMGB1 signalling) and tissue remodelling (osteoarthritis 
pathway and integrin signalling). Despite the converging effects of culture, PCTS display species-, organ- and pathology-
specific differences in the regulation of genes and canonical pathways. The underlying pathology in human diseased PCTS 
endures and influences biological processes like cytokine release. Our study reinforces the use of PCTS as an ex vivo fibrosis 
model and supports future studies towards its validation as a preclinical tool for drug development.
Keywords Precision-cut tissue slices · Fibrosis · Inflammation · Human tissue · RNA sequencing · Ingenuity pathway 
analysis
Introduction
The idea of tissue slices has been around for almost a cen-
tury (Warburg 1923; Krebs 1933). However, it was not until 
1980, when Krumdieck et al. (1980) developed a tissue slicer 
that enabled cutting of thin slices with precise thickness, the 
tissue slice technique received renewed attention. Precision-
cut tissue slices (PCTS) capture the complex organotypic 
three-dimensional cellular structure, as each slice retains all 
cell types present in their original tissue-matrix configura-
tion (de Graaf et al. 2007).
PCTS model is a promising tool for pharmaceutical 
research and development: it could bridge the translational 
gap between in vitro and in vivo studies. Many drugs fail 
development, suggesting that conventional preclinical mod-
els lack translatability and predictiveness for human dis-
eases. In turn, the PCTS model is versatile, as both rodent 
and human tissue, healthy and diseased, can be used to pre-
pare slices. In contrast to in vivo studies, PCTS offer the 
possibility for simultaneous use of different organs from the 
same animal, as well as for evaluation of multiple experi-
mental conditions at once since multiple slices can be pre-
pared from one organ. The use of human tissue significantly 
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improves the clinical relevance of PCTS by eliminating 
the need of cross-species translation. Therefore, the PCTS 
model contributes to the substantial reduction of animal use 
in biomedical research.
PCTS are used for a wide range of applications due to 
the fact that slices can be prepared from virtually any solid 
organ [liver, kidney, heart and several tumor types (Bull 
et al. 2000; Parajuli and Doppler 2009; Luangmonkong et al. 
2017; Stribos et al. 2017)] as well as from non-solid organs 
[intestine and lung (Wohlsen et al. 2001; de Kanter et al. 
2005)]. The applications of PCTS evolved from studies of 
liver functions (Krumdieck et al. 1980) to the use in xeno-
biotic metabolism, transport and toxicity research (de Graaf 
et al. 2007; Li et al. 2016; Vatakuti et al. 2016). Slices can be 
used to study the ischemia/reperfusion damage (’t Hart et al. 
2005; Lee et al. 2008) and uptake of nanoparticles as carri-
ers for gene therapy agents (Osman et al. 2018). Recently, 
the application of PCTS was further extended to study the 
mechanism of fibrosis, which is characterized by the excess 
deposition of extracellular matrix. It has been shown that 
PCTS from different organs develop inflammatory and 
fibrogenic responses during culture, making PCTS a suit-
able model for fibrosis and analysing the effect of antifibrotic 
compounds (Kasper et al. 2004; Westra et al. 2014, 2016; 
Pham et al. 2015; Stribos et al. 2016; Alsafadi et al. 2017; 
Luangmonkong et al. 2017, 2018). Furthermore, PCTS gen-
erated from human diseased organs allow the investigation 
of fibrosis in situ, as we previously showed for human cir-
rhotic liver PCTS (Luangmonkong et al. 2017).
Despite the extensive applications of PCTS, its recogni-
tion is limited by the lack of validation and molecular char-
acterization. As a step towards validation, we attempted to 
describe the transcriptional changes in PCTS during cul-
ture by deep sequencing. In the past decade, next-generation 
sequencing (NGS) revolutionized the fields of genetics and 
biology, providing highly sensitive measurement of whole 
transcriptomes. RNA-Seq, as one of NGS applications, ena-
bles high-throughput transcriptomic analysis of gene expres-
sion profiles at the tissue level (Metzker 2010) and can be 
applied to various species and sources of RNA/DNA. The 
main advantages of RNA-Seq include high detection sensi-
tivity, accuracy, increased automation and relatively low cost 
(Yadav et al. 2014).
The present study provides a comprehensive characteriza-
tion of the dynamic transcriptional changes in PCTS during 
culture, and is divided into two parts. In Part I, we performed 
total RNA sequencing of murine and human PCTS pre-
pared from various healthy organs (liver, kidney and gut) to 
investigate species and organ differences in culture-induced 
responses. In Part II of this study, we characterized molec-
ular processes that occur in human PCTS generated from 
diseased (fibrotic) tissues during culture, and performed 
in-depth comparative analysis of transcriptomic profiles 
of human diseased and healthy control PCTS. Particular 
emphasis was placed on inflammation- and fibrosis-asso-
ciated processes in PCTS. The findings largely contribute 
to our understanding of molecular mechanisms involved in 
PCTS culture, laying the foundation for the future validation 
of PCTS as an ex vivo injury/fibrosis model and a preclinical 
tool for drug development.
Methods
Ethical statement
The animal experiments were approved by the Animal 
Ethics Committee of the University of Groningen (DEC 
6416AA-001).
The use of human material was approved by the Medical 
Ethical Committee of the University Medical Centre Gron-
ingen (UMCG), according to Dutch legislation and the Code 
of Conduct for dealing responsibly with human tissue in the 
context of health research (www.feder a.org), refraining the 
need of written consent for ‘further use’ of coded-anony-
mous human tissue.
Animal and human material
Adult, 8–10 weeks old, male C57BL/6 mice (De Centrale 
Dienst Proefdieren, UMCG, Groningen, The Netherlands) 
with an average weight of 28.9 g (± 1.1) were housed under 
standard conditions with free access to chow and water. Five 
different animals were used for each organ. Murine organs 
were harvested after a terminal procedure performed under 
isoflurane/O2 anaesthesia and stored in ice-cold tissue pres-
ervation solution (University of Wisconsin (UW) for liver, 
kidney and lung, or supplemented Krebs–Henseleit buffer 
(KHB) for jejunum, ileum and colon).
Human tissue was obtained from surplus resected 
material from patients with varying underlying diseases 
(Table 1). Patient demographics are included in Table S1. 
The tissue from three to five patients was used for obtaining 
PCTS (biological replicates). Ice-cold UW and KHB were 
used for human material preservation until further use.
Preparation of precision‑cut tissue slices (PCTS)
PCTS from mouse and human liver and intestine were pre-
pared as previously described (de Graaf et al. 2010). Prepa-
ration of mouse and human kidney slices was described by 
Stribos et al. (Stribos et al. 2016, 2017), while lung slices 
were prepared as described by Ruigrok et al. (2017). Slices 
were obtained with Krumdieck slicer filled with ice-cold 
KHB supplemented with 25 mM d-glucose (Merck, Darm-
stadt, Germany), 25 mM  NaHCO3 (Merck), 10 mM HEPES 
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(MP Biomedicals, Aurora, OH, USA), saturated with car-
bogen (95%  O2/5%  CO2), pH 7.42. Slices were incubated 
in Williams’ medium E (WME, with l-glutamine, Ther-
moFisher Scientific, Landsmeer, The Netherlands) or Dul-
becco’s modified Eagle medium (DMEM, with l-glutamine, 
ThermoFisher Scientific) with different supplements. 
Table 2 summarizes the details of the preparation and incu-
bation of murine and human PCTS.
Liver, kidney and lung PCTS had a wet weight of 4–5 mg 
and thickness of 200–250 μm, whereas intestinal slices had 
a wet weight of 1–2 mg and thickness of 300–400 μm. The 
preparation of human intestinal slices differed from mouse: 
after the luminal surface of human gut was flushed with 
ice-cold oxygenated KHB, the submucosa, muscular layer 
and serosa were gently removed from the intestinal mucosa.
All PCTS were cultured for 48 h at 37 °C in an 80% 
 O2/5%  CO2 atmosphere while shaken at 90 rpm. No pre-
incubation step was used for culturing PCTS. Medium was 
refreshed after 24 h.
Sample collection
PCTS were collected immediately after slicing (0 h) and 
after 48 h incubation. For each animal/donor and time point, 
we used three slices for the viability assay, and four slices 
for NGS analysis. Samples were snap-frozen and stored at 
Table 1  Sources of human 
material
ESLD end-stage liver disease, ESRD end-stage renal disease, NA not available
Tissue Healthy Diseased
Liver Partial hepatectomy, organ donation Liver transplantation (recipient with ESLD)
Kidney Tumor nephrectomy ESRD nephrectomy, transplantectomy
Jejunum Pancreaticoduodenectomy NA
Ileum Right hemicolectomy Right hemicolectomy (patients with Crohn’s disease)
Colon Right hemicolectomy NA
Lung NA Idiopathic pulmonary fibrosis
Table 2  Preparation and incubation of human and murine PCTS
Suppliers: WME GlutaMAX™ and DMEM GlutaMAX™ were purchased from ThermoFisher Scientific (Landsmeer, The Netherlands), d-glu-
cose from Merck (Darmstadt, Germany), gentamycin and fungizone from Invitrogen (Paisley, Scotland), ciprofloxacin from Sigma-Aldrich 
(Saint Louis, USA), non-essential amino acid mixture, penicillin and streptomycin from Life Technologies (Bleiswijk, The Netherlands), fetal 
calf serum from Biowest (Nuaillé, France)
UW University of Wisconsin preservation solution, KHB Krebs–Henseleit buffer, WME Williams’ medium E, DMEM Dulbecco’s modified 
Eagle medium, FCS fetal calf serum





Liver – UW WME GlutaMAX™ – Mouse and human: 12-well plate; 
1.3 mL per welld-Glucose 25 mM
Gentamycin 50 μg/ml
Kidney – UW WME GlutaMAX™ – Mouse and human: 12-well plate; 





3% agarose in 0.9% 
NaCl
KHB WME GlutaMAX™ – Mouse: 24-well plate; 0.5 mL per 
well





Lung 1.5% agarose in 0.9% 
NaCl
UW DMEM GlutaMAX™ – Mouse and human: 12-well plate; 
1.3 mL per welld-Glucose 25 mM
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− 80 °C until further use. Additionally, culture medium from 
the wells with human slices used for NGS was collected at 
24 h and 48 h, then stored at − 80 °C.
Viability
Viability of the tissue slices was measured with adenosine 
triphosphate (ATP) bioluminescence kit (Roche Diagnostics, 
Mannheim, Germany), as previously described (de Graaf 
et al. 2010). The ATP (pmol) was normalized to the total 
protein content (μg) estimated by the Lowry assay (Bio-Rad 
DC Protein Assay, Bio Rad, Veenendaal, The Netherlands).
RNA isolation and next‑generation sequencing 
(NGS)
Total ribo-depleted RNA was extracted from PCTS semi-
automatically with MagMax AM1830 kit (Fisher Scientific 
GmbH, Schwerte, Germany). Reverse transcription was 
performed with 100 ng RNA using TruSeq Stranded Total 
RNA LT Sample Prep Kit with Ribo-Zero™ H/M/R (Order 
#RS-122-2502, Illumina Inc, San Diego, CA, USA). The 
kit covers the transcription of protein-coding, non-coding 
and non-polyadenylated RNAs, while depleting cytoplasmic 
ribosomal RNA. The sequencing libraries were constructed 
according to the recommended procedures. Sequencing was 
carried out using the Illumina TruSeq methods (cluster kit 
TruSeq SR Cluster Kit v3-cBot-HS GD-401-3001, sequenc-
ing kit TruSeq SBS Kit HS- v3 50-cycle FC-401-3002) as 
85 bp, single reads and 7 bases index read at depth of 50–60 
million reads per sample on an Illumina HiSeq 3000 system.
Of note, the available lung PCTS (from five healthy mice 
and one patient with idiopathic pulmonary fibrosis) were 
sequenced together with other samples, but were excluded 
from the downstream analyses due to the lack of human 
healthy lung samples and insufficient number of biological 
replicates for human diseased lung PCTS.
NGS bioinformatics analysis
The processing pipeline was previously described (Söllner 
et al. 2017). RNA-Seq reads from all samples were aligned 
to the human and mouse reference genomes, respectively 
(Ensembl 70; http://www.ensem bl.org) using STAR. Gene 
expression levels were quantified using Cufflinks software 
(Trapnell et al. 2013) to obtain the reads per kilobase of 
transcript per million mapped reads (RPKM), as well as read 
counts. The matrix of read counts and the design files were 
imported to R, normalization factors were calculated using 
trimmed mean of M values and subsequently normalized 
before further downstream analysis.
Differentially expressed genes (DEGs) were identified for 
all experimental groups. Paired differential gene expression 
(e.g. PCTS 48 h vs. 0 h) was assessed by Limma with a 
paired design for multiple samples originated from the same 
animal/donor. Fold changes (FC) were  log2 normalized and 
p values were adjusted for false discovery rate (FDR) by 
applying Benjamini–Hochberg correction. Genes with a padj 
value ≤ 0.01 and  log2 (FC) ≥ 1 were considered as differen-
tially expressed. Graphs illustrating top 10 regulated DEGs 
were created using D3.js JavaScript library (http://d3js.org/).
Principal component analysis and hierarchical clustering
Principal component analysis (PCA) was performed on 
limma voom-transformed log (counts per million) using R. 
We used the first three principal components (PCs) to pro-
duce two-dimensional plots with Python scientific library 
Matplotlib. The heatmap of  log2 (FC) gene expression of 
murine and human PCTS was generated with the online tool 
Morpheus (https ://softw are.broad insti tute.org/morph eus/).
Pathway analysis
Functional pathway analysis of differentially expressed 
gene sets was performed with QIAGEN  Ingenuity® Path-
way Analysis software  (IPA®, QIAGEN Redwood City, CA, 
USA) for the following sets of genes: (1) culture-induced 
DEGs in murine and human tissue slices; (2) DEGs between 
diseased and healthy control human PCTS that were concur-
rently present at 0 h or 48 h; (3) common DEGs in cultured 
healthy and diseased human PCTS. These sets of DEGs with 
corresponding gene identifiers (Ensembl gene ID),  log2 (FC) 
values and adjusted p values were uploaded into the IPA to 
reveal the enriched canonical signalling pathways accord-
ing to the Ingenuity Pathways Knowledge Base (IPKB). To 
assess whether a biological pathway significantly underlies 
the data, we used two independent scores: a p value (i.e. 
Fisher’s exact test p value) that measures significance of 
overlap between observed and predicted sets of regulated 
genes, and a z-score that measures the match of observed 
and predicted up-/downregulation patterns (Krämer et al. 
2014). The sign of z-score determines whether the pathway 
is predicted to be activated or inhibited. In cases of insuffi-
cient literature-based evidence, the z-score is undetermined. 
Canonical pathways with p value ≤ 0.01 and |z-score| ≥ 2 
were considered significantly regulated (Krämer et al. 2014).
Cytokine release
Culture supernatants, collected after 24 h and 48 h, were 
used for quantification of chemokine and cytokine levels 
by Meso Scale Discovery (MSD) multiplex assay. The 
mesoscale platform (Meso Scale Discovery, Gaithersburg, 
Md., USA) employs electroluminescence technology allow-
ing for simultaneous measurement up to ten analytes with 
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high sensitivity. Samples were measured with MSD SEC-
TOR S600 Reader using MSD DISCOVERY Workbench 
Software according to the manufacturer’s instructions. 
The list of selected analytes with corresponding catalogue 
numbers is provided in Table S2. Measurement of 24-h and 
48-h medium samples was carried out separately; abso-
lute concentrations (pg/mL) were normalized to the nega-
tive control (i.e. medium that was neither in contact with 
PCTS nor under influence of incubator conditions). For each 
cytokine, we used the sum of 24-h and 48-h measurements 
to determine the total cytokine concentration. Only those 
cytokines that had a total concentration higher than 20 pg/
mL in at least one experimental group and were regulated 
on gene level [with a padj value ≤ 0.01 and  log2 (FC) ≥ 1] 
during culture were included for further analysis. Data are 
presented as heatmap of normalized absolute concentrations 
of secreted cytokines, with applied average-linkage cluster-
ing (performed using Pearson correlation). The heatmap was 
generated using the online tool Morpheus (https ://softw are.
broad insti tute.org/morph eus/). The correlation between 
cytokine release (as measured by MSD) and gene expression 
was made by comparing total cytokine concentrations to the 
average gene expression (RPKM values) of PCTS at 0 h and 
48 h (geometric mean from each timepoint). We applied a 
simple linear regression model (TIBCO Spotfire Analyse 
7.11.0) and resulting r2 coefficient was used to assess the 
strength of the correlation.
Part I: Next‑generation sequencing reveals 
in‑depth features of healthy murine 
and human precision‑cut tissue slices
Results of Part I
Part I of this study was undertaken to characterize the 
transcriptional profiles of murine and human PCTS as well 
as their change over time in culture. Only healthy tissues 
were used to prepare murine and human PCTS for Part I 
study. Figure 1 depicts the Part I workflow. We cultured 
murine and human PCTS for 48 h as previous studies 
reported that at 48 h slices largely retain tissue viabil-
ity and structural integrity (Stribos et al. 2016; Luang-
monkong et al. 2017; Bigaeva et al. 2019). Lung PCTS 
were prepared and cultured as described in “Methods”, but 
hereafter excluded from functional analyses (and, there-
fore, omitted in Fig. 1) because we were only able to col-
lect lung slices from healthy mice, but not from healthy 
human donors due to the extremely limited availability 
of resected human lung tissue. Figure S1a, b shows that 
all PCTS remained viable during the 48 h of culture. We 
observed high variability for the RNA quality across the 
organs, with intestine PCTS having generally the lowest 
RNA quality based on RNA integrity numbers (data not 
shown). Nevertheless, since the total RNA protocol allows 
for sequencing samples with partially degraded RNA, we 
could include all samples into the analysis. After sequenc-
ing, we obtained for each sample 25–75 million single end 
reads with a rate of 40–60% unique mapping to exonic 
regions of non-ribosomal protein-coding genes (data not 
shown). Consequently, the sequencing data were sufficient 
to investigate differential expression between all groups 
of interest.
As a preliminary experiment, we investigated the 
sequencing variability of mouse liver PCTS obtained from 
one animal. We observed a very low intra-individual vari-
ability in murine PCTS; therefore, we only included one 
single mouse organ slice per animal per condition into the 
analysis. In case of human PCTS, we included 3–4 slices 
per donor per condition (technical replicates) since the vari-
ability was generally higher in human samples compared to 
mouse. However, these replicates showed a very high repro-
ducibility and low intra-individual variability, similar to the 
animal PCTS.
Fig. 1  Study workflow. Precision-cut tissue slices (PCTS) were pre-
pared from murine or human tissues (liver, kidney, jejunum, ileum 
and colon) using Krumdieck tissue slicer and incubated for 48  h. 
Samples were collected at 0 h (prior incubation) and at 48 h for via-
bility measurement and sequencing analysis
3554 Archives of Toxicology (2019) 93:3549–3583
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(Ia) Principal component analysis and hierarchical 
clustering
As a first step of the Part I study, we analysed murine and 
human PCTS data by principal component analysis (PCA) 
to investigate which experimental factors (organ, time in 
culture) have the strongest effect on the variance of the 
data. Two-dimensional plots based on first three compo-
nents (PC1, PC2 and PC3) are shown in Fig. 2a–d. First two 
dimensions (PC1 vs. PC2) clearly separated murine PCTS 
samples by the tissue type (Fig. 2a). Mouse liver PCTS 
formed a distinct cluster along PC1 (bottom left). A sec-
ond cluster is composed of the kidney samples (top left). 
All samples from intestinal PCTS (i.e. jejunum, ileum and 
colon) clustered together at the right part of the plot. In PC1 
vs. PC3 (Fig. 2b), we observed clustering of the mouse sam-
ples based on culture time: 0-h PCTS (bottom of the plot) 
were separated from 48-h PCTS (top of the plot). Similar 
to murine PCTS, PC1 of human PCTS showed a consistent 
separation by tissue type with the liver samples clustering 
on the left with negative PC1 values, GI tract samples on 
the right with positive PC1 values and the kidney samples 
in between (Fig. 2c, d). PC3 showed an additional separa-
tion between human liver and kidney PCTS, whereas PC2 
separated them by time in culture. Percentages of explained 
variance for each of the first three principal components are 
indicated in Fig. S2, which illustrates PCA results for all 
analysed PCTS (healthy murine PCTS in Fig. S2a, b; healthy 
and diseased human PCTS in Fig. S2c, d), including murine 
and human lung slices. Overall, PCA showed consistently 
that both murine and human PCTS can be distinguished by 
the tissue type and incubation time point, indicating that 
these two factors are the main drivers of variance involved 
in PCTS culture. Hierarchical clustering of differentially 
expressed genes with time in culture  [log2 (FC); see Fig. 2e] 
showed that murine intestinal PCTS clustered first together 
and then with human intestinal PCTS. Along with species-
specific clusters of differentially expressed genes (DEGs) 
(which might also originate from batch effects from compar-
ing the results of two sequencing experiments, i.e. murine 
and human PCTS), there were organ-specific clusters of 
DEGs in murine and human PCTS, which have been inves-
tigated in more detail in the next section.
(Ib) Culture‑induced changes in transcriptional 
profiles of murine and human PCTS
Total number of differentially expressed genes
To determine the global changes in the transcriptional 
profiles of PCTS during culture, we identified genes dif-
ferentially expressed prior (0 h) and after culture (48 h) in 
murine and human PCTS from the five studied organs. We 
selected DEGs based on  log2 (FC) ≥ 1 and padj value ≤ 0.01. 
Figure 3a, b illustrates the total numbers of identified DEGs 
(upregulated and downregulated) in murine and human 
PCTS from various organs. Figure S1c, d shows volcano 
plots that summarize FC and significance for all genes in 
each comparison. Lists of all DEGs in murine and human 
PCTS are provided in File S1. Generally, the observed tran-
scriptional changes in PCTS during culture were strong 
because the number of DEGs was in the order of thousands. 
Interestingly, human jejunum PCTS had the lowest num-
ber of DEGs (563) compared to other human organs. The 
ratio between upregulated and downregulated DEGs was 
approximately 1:1 for all PCTS, except for mouse colon 
and human kidney, where the number of downregulated 
DEGs reached ≥ 60%. These results confirm that PCTS cul-
ture induced substantial changes in gene expression in both 
mouse and human tissues.
For a more detailed analysis of the transcriptional changes 
in each organ, we cross-referenced the DEGs in murine and 
human PCTS (with 1:1 homology) to identify which genes 
commonly expressed in both species are changed in the same 
or opposite direction. Figure 3c illustrates the pairwise com-
parisons of murine and human PCTS per organ. Although 
murine and human PCTS shared genes changed in the same 
direction during culture, the majority of DEGs (> 55%) were 
regulated antagonistically or solely in one species. On the 
other hand, 10–40% of downregulated or upregulated DEGs 
were shared in expression and direction of change between 
murine and human PCTS. Due to the fact that the total num-
bers of DEGs in human PCTS were generally lower than in 
murine PCTS, the ratio of common vs. different DEGs was 
higher in human PCTS. As an example, the common genes 
(125 DEGs) between mouse and human jejunum PCTS rep-
resented 42% of total human DEGs and only 6% of mouse 
DEGs (Fig. 3c). Taken together, we showed that murine and 
human PCTS shared sets of similarly regulated genes during 
culture; however, most of the genes were not regulated in the 
same direction (File S2).
Top ten regulated genes in murine and human PCTS 
during culture
To further investigate transcriptional changes in PCTS, we 
aimed to determine the most differentially regulated genes 
in every mouse and human organ. Figure 4 illustrates the 
top ten upregulated genes and top ten downregulated genes 
with the most pronounced change in expression after 48 h 
[padj value ≤ 0.01 and  log2 (FC) ≥ 1]. The top ten genes were 
ranked based on the absolute  log2 (FC) values. Additional 
information regarding ensemble gene ID, target class and 
function of proteins encoded by the top ten genes is provided 
in Table S3 (mouse) and Table S4 (human). Complete DEGs 
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Fig. 2  Principal component analyses (PCA) and hierarchical cluster-
ing analysis in murine and human PCTS. PCA scatter plots of dimen-
sions PC1 vs. PC2 and PC1 vs. PC3 in mouse PCTS (a and b) and 
human PCTS (c and d); n = 5. Samples are coloured by tissue type 
and shaped by incubation time point. Each symbol in the plots for 
murine and human PCTS represents total mRNA sequencing from 
a single technical replicate. e Transcriptomic profiles of murine and 
human PCTS during culture. The heatmap of  log2 (FC) values illus-
trates expression of 8360 genes (with padj ≤ 0.01) regulated during 
48-h culture in murine and human PCTS (1:1 homology). Average-
linkage hierarchical clustering was performed using Pearson correla-
tion
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lists can be found in File S1. Further observations are based 
solely on the lists of the top ten regulated genes.
Murine PCTS The most upregulated genes in murine PCTS 
during culture were mainly related to inflammation (Il11, 
Il6, Cxcl1, Cxcl2, Cxcl5, Cxcl5, Ccl2, Ccl7, Ccl20 and 
Gpnmb) and extracellular matrix (ECM) organization 
(Mmp3, Mmp10, Mmp13, Timp1). Inflammatory gene Il11 
was commonly upregulated in mouse kidney, ileum and 
colon; Il6 was common for kidney and ileum. Mmp3 was 
highly upregulated in all mouse intestinal PCTS; jejunum 
and colon additionally highly expressed Mmp10. Mouse 
kidney showed highly upregulated Havcr1, encoding kidney 
injury molecule-1 (KIM-1), a marker of acute renal tubular 
injury. Moreover, genes encoding enzymes were often pre-
sent in top ten upregulated DEGs (Sult1e1, Has2, Tat, Sis) 
in various organs.
The most downregulated genes can be grouped in two 
main categories: metabolic enzymes (Cyp2d12, Cyp7a1, 
Sult2a8, Elovl3, etc.) and transporters (Slc5a4a, Slc5a11, 
Slc5a12, Slc13a2OS, Slc13a2, Slc22A28, Slc22a30, Slc28a1, 
Slc34a1, Slc34a3, Slco1a4). Mouse liver PCTS showed the 
highest number of genes encoding enzymes. Most genes 
encoding transporters were found in top ten downregulated 
genes in mouse jejunum, whereas no such genes were pre-
sent in mouse colon. However, genes encoding transporters 
were also present in top ten upregulated genes, as shown by 
Slc7a11 in mouse liver and kidney PCTS.






























Murine healthy PCTS Human healthy PCTS
Fig. 3  Differentially expressed genes in murine and human PCTS 
during culture. DEGs were defined as genes with  log2 (FC) ≥ 1 and 
padj value ≤ 0.01. a Total number of DEGs, upregulated and down-
regulated, in mouse PCTS. b Total number of DEGs, upregulated 
and downregulated, in human PCTS. Full lists of identified DEGs are 
provided in File S1. c Venn diagrams showing the number of unique 
genes regulated in mouse and human PCTS and the number of over-
lapping genes. Red colour indicates upregulated set of DEGs, green 
colour indicates the downregulated (colour figure online)
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Human PCTS Similar to murine PCTS, the top ten upregu-
lated genes in human PCTS belonged mostly to inflamma-
tion (IL11, IL6, CXCL5, CXCL8, CSF3), ECM organization 
(MMP1, MMP3, MMP10, TFPI2) and catalysts (DUOXA2, 
ATP6V0D2, HS3ST2, CEMIP). Human ileum and colon 
showed upregulation for most of these genes, while jeju-
num and liver had less inflammation-related genes and 
human kidney had no ECM-related genes. MMP1, MMP3 
and MMP10 were found in all human PCTS, except kid-
ney. IL11 was common in human kidney, ileum and colon; 
CXCL5 was shared by all intestinal PCTS, while ileum and 
colon additionally highly expressed CXCL8. Human jeju-
num PCTS showed highly upregulated enzyme-coding 
gene DUOX2 and associated gene DUOXA2; HS3ST2 was 
found in top ten upregulated genes in human liver and kid-
ney. Moreover, top ten upregulated genes in human kidney 
included several non-protein-coding transcripts.
Similar to murine PCTS, top ten downregulated genes in 
human PCTS included genes encoding enzymes (CYP8B1, 
CYP2W1, ATP1A2, HMGCS2, PLD4, HSD3B1, G6PC, 
FMO1, CA1 and ADH1C) and transporters (SLCO2A1, 
SLC4A1, SLC22A6, SLC22A7, SLC30A10, SLC34A1, 
BEST2, SCNN1G). Gene GP2 was commonly downregu-
lated in human kidney, ileum and colon. Of note, ten novel 
transcripts were identified among the top downregulated 
genes in human liver, kidney, jejunum and ileum.
Commonly regulated top genes in  murine and  human 
PCTS Genes that were common across most of the mouse 
and human organs included IL11, MMP3 and MMP10 
(Fig. 4). Moreover, CXCL5 was highly expressed by human 
intestinal PCTS and mouse liver. In turn, SERPINHB2, 
encoding PAI-2, was upregulated in mouse liver, human 
kidney and human colon PCTS. Same organs, but from 
different species (mouse and human), shared expression of 
several transcripts: for example, mouse and human kidney 
PCTS had common upregulation of IL11 and downregula-
tion of SLC34A1; mouse and human jejunum shared high 
expression of ANXA10 and MMP10; mouse and human 




Fig. 4  Top ten significantly upregulated and downregulated DEGs 
in murine and human PCTS. Genes were selected based on the  log2 
(FC) values. a Mouse PCTS; b human PCTS. Full lists of DEGs are 
provided in File S1, and the detailed description of top ten genes is 
provided in Table S3 (mouse) and Table S4 (human)
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Enriched biological pathways in murine and human 
PCTS in culture
Next, we determined the biological processes associated 
with the culture-induced changes reflected by the DEGs. For 
this purpose, we performed functional enrichment analysis 
using IPA to identify canonical pathways altered in murine 
and human PCTS during culture. The ranking of canonical 
pathways was based on the z-score: a z-score ≥ 2 (predictor 
of activation) or ≤ − 2 (predictor of inhibition) was consid-
ered as meaningful (Krämer et al. 2014). Pathways with a p 
value ≥ 0.01 and unidentified z-score were omitted from the 
analysis. Figures 5 and 6a show the top five canonical path-
ways activated or inhibited during culture in murine PCTS 
and human PCTS, respectively. To make a thorough exami-
nation, further observations are based on complete lists of 
significantly altered canonical pathways in PCTS that are 
provided in Figs. S3–9. We found that six canonical path-
ways activated during culture were present in most mouse 
organs and, interestingly, they were similar to the pathways 
prevalent in human PCTS. These included IL-6 signalling, 
IL-8 signalling, HMGB1 signalling, osteoarthritis pathway, 
Canonical Pathway z-score -log(p-value) Size Downregulated (%) Upregulated (%) Overlap (%)
iNOS Signaling 3,64 2,95 45 20 69 89
PI3K/AKT Signaling 3,57 2,23 131 28 59 87
LPS/IL-1 Mediated Inhibition of RXR Function 3,39 19,70 222 55 27 82
HMGB1 Signaling 3,32 2,18 139 30 55 85
Agrin Interactions at Neuromuscular Junction 3,14 3,17 75 37 56 93
Ephrin Receptor Signaling (*) 4,26 8,64 179 23 66 89
IL-6 Signaling 4,18 7,67 134 20 66 87
HMGB1 Signaling 4,11 7,88 139 24 60 85
Actin Nucleation by ARP-WASP Complex (*) 3,90 6,30 62 15 74 89
Acute Phase Response Signaling (*) 3,87 5,56 176 29 57 86
Osteoarthritis Pathway (*) 3,91 10,00 212 25 57 82
Cholecystokinin/Gastrin-mediated Signaling 3,78 2,18 107 27 61 88
IL-8 Signaling (*) 3,68 3,30 203 31 58 89
STAT3 Pathway 3,31 4,18 103 32 64 97
IL-6 Signaling (*) 3,18 2,04 134 26 60 87
IL-6 Signaling 4,22 3,12 134 28 58 87
Acute Phase Response Signaling 4,00 3,54 176 37 48 86
Toll-like Receptor Signaling 3,90 2,30 76 30 57 88
STAT3 Pathway 3,67 4,70 103 36 61 97
NF-κB Signaling 3,27 3,98 187 33 51 84
HMGB1 Signaling (*) 2,65 4,31 139 31 52 85
IL-8 Signaling (*) 2,53 5,06 203 34 54 89
ILK Signaling 2,47 8,01 197 35 48 84
NRF2-mediated Oxidative Stress Response 2,36 3,49 199 34 50 86
Ceramide Signaling 2,36 2,23 99 38 54 93
Oxidative Phosphorylation -7,35 8,98 109 77 6 83
LXR/RXR Activation (*) -5,61 15,30 121 53 31 83
Nicotine Degradation II (*) -5,58 7,21 65 68 6 74
Nicotine Degradation III -5,01 5,62 56 66 7 73
Superpathway of Cholesterol Biosynthesis -4,90 11,50 28 89 7 96
Oxidative Phosphorylation -7,00 7,61 109 81 2 83
PPAR Signaling -5,10 3,92 101 20 63 83
PPARα/RXRα Activation -4,81 5,30 186 33 50 83
LXR/RXR Activation (*) -4,64 5,13 121 34 50 83
TCA Cycle II (Eukaryotic) -3,87 4,85 24 92 4 96
PPAR Signaling (*) -4,16 2,56 101 25 58 83
LXR/RXR Activation -4,04 2,78 121 32 50 83
Inhibition of Matrix Metalloproteases -2,98 7,04 39 15 72 87
PTEN Signaling -2,96 2,53 125 39 50 91
Fatty Acid β-oxidation I -2,84 4,26 32 72 25 97
PPAR Signaling (*) -4,24 3,36 101 29 53 83
LXR/RXR Activation (*) -4,12 3,44 121 42 40 83
PPARα/RXRα Activation -3,20 3,47 186 39 44 83
Calcium-induced T Lymphocyte Apoptosis -3,13 3,64 66 50 26 76
iCOS-iCOSL Signaling in T Helper Cells -2,79 3,62 123 43 36 80
Calcium Signaling -3,89 6,50 206 48 27 77
Synaptic Long Term Depression -3,89 4,39 180 48 34 83
Neuropathic Pain Signaling In Dorsal Horn Neurons -3,84 2,89 115 53 30 85
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells -2,84 2,67 112 51 33 87





















































Fig. 5  Top five canonical pathways that were significantly changed 
during culture in murine PCTS as identified by ingenuity pathway 
analysis (IPA). Only pathways with p value ≤ 0.01 and a z-score ≥ 2 
(predictor of activation) or ≤ − 2 (predictor of inhibition) were 
included. Pathway size (i.e. total number of genes in a pathway), per-
centage of significantly downregulated (green bars) and upregulated 
(red bars) genes in a given pathway, and percentage of overlap with 
the dataset (grey bars) are indicated for each pathway. Pathways in 
blue colour are most common across the organs. Pathways marked 
with (asterisk) are shared between mouse and human respective 
organ. Full lists of significantly changed pathways in murine PCTS 
from each organ are provided in Fig. S3–5 (colour figure online)
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Canonical Pathway z-score -log(p-value) Size Downregulated (%) Upregulated (%) Overlap (%)
Integrin Signaling 4,26 6,23 219 23 51 75
IL-8 Signaling 3,78 6,26 203 26 52 78
Signaling by Rho Family GTPases 3,68 4,26 252 28 50 79
Rac Signaling 3,66 2,16 123 23 50 75
Actin Nucleation by ARP-WASP Complex 3,44 4,43 62 18 58 76
PI3K/AKT Signaling 4,49 2,14 131 23 53 76
Actin Nucleation by ARP-WASP Complex (*) 4,08 4,34 62 18 58 76
Ephrin Receptor Signaling (*) 3,18 2,60 179 32 47 80
Acute Phase Response Signaling (*) 3,00 3,56 176 32 50 82
Remodeling of Epithelial Adherens Junctions 2,83 2,32 69 17 57 74
Acute Phase Response Signaling 3,32 2,70 176 38 45 82
Osteoarthritis Pathway (*) 3,00 5,87 212 29 51 80
IL-6 Signaling (*) 3,00 2,51 134 28 48 76
Superpathway of Cholesterol Biosynthesis 2,71 11,10 28 18 64 89
IL-8 Signaling (*) 2,71 2,23 203 33 43 78
Osteoarthritis Pathway 3,67 6,51 212 28 52 80
Role of IL-17F in Allergic Inflammatory Airway Diseases 3,61 5,04 46 15 54 70
TREM1 Signaling 3,44 5,29 75 24 60 84
IL-8 Signaling 3,31 4,49 203 25 52 78
Dermatan Sulfate Biosynthesis 3,05 3,17 59 31 49 80
IL-8 Signaling (*) 4,73 3,51 203 25 53 78
HMGB1 Signaling (*) 4,52 7,95 139 21 55 76
PI3K/AKT Signaling 4,38 3,21 131 18 57 76
Acute Phase Response Signaling 4,22 5,14 176 22 61 82
TREM1 Signaling 4,15 3,09 75 20 63 84
LXR/RXR Activation (*) -5,17 25,90 121 62 32 94
Nicotine Degradation II (*) -3,96 5,15 65 57 18 75
Estrogen Biosynthesis -3,90 6,43 41 61 22 85
Fatty Acid β-oxidation I -3,77 7,80 32 69 22 94
Melatonin Degradation I -3,71 4,09 65 58 20 78
Neuropathic Pain Signaling In Dorsal Horn Neurons -3,77 2,25 115 50 31 83
LXR/RXR Activation (*) -3,21 4,80 121 55 40 94
Fatty Acid β-oxidation I -3,21 3,40 32 81 13 94
Serotonin Degradation -3,16 4,84 77 61 16 77
Ethanol Degradation II -2,98 5,69 37 68 14 81
PPAR Signaling (*) -2,65 2,13 101 20 54 74
LXR/RXR Activation (*) -3,44 4,07 121 33 61 94
PPAR Signaling (*) -3,44 3,41 101 18 56 74
Nicotine Degradation II -2,89 2,29 65 58 15 75
Estrogen Biosynthesis -2,33 2,35 41 63 20 85
Superpathway of Melatonin Degradation -2,31 2,03 70 63 16 80
Oxidative Phosphorylation -6,86 13,40 109 72 4 75
PPAR Signaling -5,24 7,16 101 16 58 74
PPARα/RXRα Activation -3,55 4,47 186 28 44 73
LXR/RXR Activation -3,53 3,51 121 35 59 94





















































b Mouse PCTS Human PCTS Common pathways
Liver 17 34 5
Kidney 62 14 10
Jejunum 28 9 4
Ileum 14 21 8
Colon 9 59 6
Liver 58 26 18
Kidney 29 16 8
Jejunum 9 1 1
Ileum 11 6 2











Fig. 6  Top five canonical pathways that were significantly changed 
during culture in human PCTS as identified by ingenuity pathway 
analysis (IPA). Only pathways with p value ≤ 0.01 and a z-score ≥ 2 
(predictor of activation) or ≤ − 2 (predictor of inhibition) were 
included. Pathway size (i.e. total number of genes in a pathway), 
percentage of significantly downregulated (green bars) and upregu-
lated (red bars) genes in a given pathway, and percentage of overlap 
with the dataset (grey bars) are indicated for each pathway. a Path-
ways in blue colour are most common across the organs. Pathways 
marked with (asterisk) are shared between mouse and human respec-
tive organ. Complete lists of significantly changed pathways in human 
PCTS from each organ are provided in Figs.  S6–9. b Based on the 
complete lists, we determined the total numbers of altered canoni-
cal pathways in murine and human PCTS, as well as the number of 
shared pathways in each organ (colour figure online)
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acute phase response signalling and LPS/IL-1-mediated 
inhibition of RXR function. Among the prevalent canoni-
cal pathways that showed inhibition during culture for 
both mouse and human organs were LXR/RXR activation, 
PPAR signalling and fatty acid β-oxidation I. Furthermore, 
three additional pathways—ceramide signalling, STAT3 
pathway and NF-κB signalling—were activated solely in 
mouse organs, while PPARα/RXRα activation pathway 
was inhibited. In turn, human PCTS additionally showed 
common activation of PI3K/AKT signalling and inhibition 
of valine degradation I. Figure 6b illustrates that all organ 
PCTS shared a number of pathways in both species, except 
for the inhibited pathways in colon. Overall, the enriched 
pathways associated with DEGs give a detailed insight into 
the biological processes that are driven by culture-induced 
transcriptional changes in PCTS.
(Ic) Regulation of selected canonical pathways 
in murine and human PCTS during culture
Since PCTS are used as a model for fibrosis and inflamma-
tion (Westra et al. 2013; Stribos et al. 2017), we focused 
on specific canonical pathways that are related to these 
pathophysiological processes, including fibrosis (and ECM 
organization), inflammation, apoptosis, hypoxia, etc. With 
this in mind, we used the aforementioned IPA to evaluate the 
changes in these pathways of interest (Fig. 7). For each path-
way, we recorded the following information: significance 
(reflected by a p value ≤ 0.01) and the direction of change 
(reflected by the z-score, when available). Genes associated 
with each selected Ingenuity canonical pathway are provided 
in File S3.
Fibrosis‑associated signalling pathways
All mouse organ PCTS showed significant changes during 
48 h of culture. Liver and ileum had the lowest number of 
significantly changed fibrosis-associated canonical pathways 
(5 out of 18), while kidney had the most pathways changed 
(17 out of 18). Based on a z-score, culture typically activated 
fibrosis pathways; with the exception of PI3K/AKT pathway, 
which was inhibited in jejunum PCTS. Compared to other 
murine organs, kidney PCTS had the highest number of the 
activated pathways (10 out of 18). In contrast, IPA could 
not predict the direction of change for any selected pathway 
in colon PCTS, although seven pathways were significantly 
changed. TGF-β signalling, one of the main drivers of fibro-
sis (Meng et al. 2016), showed a significant change during 
culture of kidney, jejunum and colon PCTS; furthermore, 
this canonical pathway was activated in kidney and ileum.
Similar to murine PCTS, all human organs showed 
significant changes in the fibrosis-related pathways dur-
ing culture (Fig. 7). The number of significantly changed 
canonical pathways (based on p value) varied, with jejunum 
PCTS having the lowest (1 out of 18) and liver and colon 
the highest (9 and 10 out of 18, respectively). The direction 
of change in the selected pathways was activation, with one 
exception—inhibition of FGF signalling in kidney PCTS. 
Most activated pathways were observed in colon PCTS (12 
out 18), followed by liver PCTS with seven pathways. The 
other three organs only showed activation for p38 MAPK 
signalling (jejunum and ileum) and PI3K/AKT signalling 
(kidney and ileum).
ECM organization
We selected two pathways for ECM organization: inhibition 
of matrix metalloproteases and integrin signalling (Fig. 7). 
Murine PCTS showed that both canonical pathways were 
significantly changed during culture in all organs, except 
inhibition of matrix metalloproteases in liver and kidney 
PCTS. Regarding the direction of change, integrin signal-
ling was activated only in kidney slices, whereas inhibition 
of matrix metalloproteases was changed in both directions: 
activated in jejunum PCTS (i.e. more inhibition of MMPs) 
and inhibited in kidney and colon PCTS (i.e. activation of 
MMPs).
As for human slices, significant inhibition of matrix met-
alloproteases (except kidney) and integrin signalling (except 
jejunum) were identified. Only integrin signalling showed 
a direction of change—activation in liver and colon PCTS.
Inflammation‑related canonical pathways
Next, we analysed 22 canonical pathways associated with 
inflammation. After culture, all murine organ PCTS showed 
a significant change for at least one-third of these pathways 
(Fig. 7). The most significant differences were observed in 
kidney PCTS (17 out of 22 pathways). Five pathways were 
significantly changed in all organ PCTS: dendritic cell matu-
ration, IL-6, IL-8, IL-10 signalling and LPS/IL-1-mediated 
inhibition of RXR function. Further, we observed that out of 
22 inflammation-associated pathways, 13 displayed a direc-
tion of change. Inhibition was observed only for one path-
way—chemokine signalling in jejunum PCTS. Kidney and 
liver slices had the most activated pathways (eight and six, 
respectively), while the other organs had a similar number 
of activated pathways (three and five).
Likewise, inflammation-associated pathways were altered 
during the culture of human PCTS. The total number of 
significantly changed pathways was smaller in human PCTS 
than in mouse. Most differences were observed for colon and 
ileum, where 14 and 11 pathways out of 22 were changed, 
respectively. The other three organs showed differences for 
only few pathways, with jejunum having the lowest number 
of significantly changed pathways (four). The evaluation 
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Fig. 7  Regulation of preselected 
pathways in murine and human 
PCTS during 48-h culture. 
Purple colour indicates a sig-
nificant pathway change based 
on a p value ≤ 0.01; whereas 
predicted pathway activation 
(A) or inhibition (I) is indicated 


































BMP signaling pathway A A
EGF Signaling
ERK/MAPK Signaling A
FGF Signaling I A
Hepatic Fibrosis / Hepatic Stellate Cell Activation
HGF Signaling A
JAK/Stat Signaling A A A
mTOR Signaling A
p38 MAPK Signaling A A A A A A
PDGF Signaling A A A
PI3K/AKT Signaling A A I A A A A A
RhoA Signaling A A A
Signaling by Rho Family GTPases A A A A
STAT3 Pathway A A A A
TGF-β Signaling A A A
VEGF Family Ligand-Receptor Interactions A A
VEGF Signaling A A A
Wnt/β-catenin Signaling
Inhibition of Matrix Metalloproteases I A I
Integrin Signaling A A A
Chemokine Signaling A I A
Dendritic Cell Maturation A A A A A
HMGB1 Signaling A A A A A A A
IL-1 Signaling A A
IL-2 Signaling A
IL-4 Signaling A
IL-6 Signaling A A A A A A
IL-7 Signaling Pathway A A
IL-8 Signaling A A A A A A A A
IL-9 Signaling
IL-10 Signaling
IL-12 Signaling and Production in Macrophages
IL-15 Signaling
IL-17 Signaling
IL-17A Signaling in Fibroblasts
iNOS Signaling A A A A
Interferon Signaling A A
LPS/IL-1 Mediated Inhibition of RXR Function A A
LPS-stimulated MAPK Signaling A A A A A
T Cell Receptor Signaling A
Th1 and Th2 Activation Pathway
Toll-like Receptor Signaling A A A A A
Apoptosis Signaling I
Cell Cycle Control of Chromosomal Replication
Cell Cycle Regulation by BTG Family Proteins A A
Cell Cycle: G1/S Checkpoint Regulation A A
Cell Cycle: G2/M DNA Damage Checkpoint Regulation A A
Cyclins and Cell Cycle Regulation I A I
Death Receptor Signaling A A A
HIPPO signaling A
Myc Mediated Apoptosis Signaling A




NRF2-mediated Oxidative Stress Response A A A A A A
Oxidative Phosphorylation I I A I I I
Atherosclerosis Signaling A
Osteoarthritis Pathway A I A A A A A A A
PPAR Signaling I I I I I I I I I I
PPARα/RXRα Activation I I I I I I I
RANK Signaling in Osteoclasts A A
Renin-Angiotensin Signaling A























































3562 Archives of Toxicology (2019) 93:3549–3583
1 3
of the z-score showed only activation as the direction of 
change. The organ with the most activated pathways was 
colon (9 out of 22). Some pathways such as dendritic cell 
maturation, HMGB1, IL-6, IL-8 signalling and LPS-stimu-
lated MAPK signalling showed activation for three or four 
human organs PCTS.
Other pathways
Furthermore, our analysis also included pathways related 
to cell cycle and apoptosis, hypoxia and oxidative stress, 
metabolism and degenerative disorders. Amongst murine 
organs, colon PCTS had the lowest number of significantly 
changed pathways, whereas kidney PCTS had the highest. 
In contrast, human liver and jejunum PCTS had the lowest 
number of significantly changed pathways and colon PCTS 
had the most. The pathways that showed significant change 
in all murine and human PCTS were HIF1α signalling, 
osteoarthritis pathway, role of osteoblasts, osteoclasts and 
chondrocytes in rheumatoid arthritis. Pathway activation was 
observed for NF-κB signalling, NRF2-mediated oxidative 
stress response and osteoarthritis pathway in both species. 
Moreover, PPAR signalling and PPARα/RXRα activation 
showed inhibition as the direction of change also in both 
species.
Differences and similarities in regulation of selected 
pathways in murine and human PCTS
The preselected pathways showed species and organ-specific 
changes during PCTS culture. In murine PCTS, ileum and 
colon PCTS had the lowest number of significantly changed 
pathways during culture, while kidney had the highest. How-
ever, we obtained different results for human PCTS: jejunum 
PCTS had the lowest number of significantly changed path-
ways during culture, whereas colon PCTS had the highest. 
As for direction of change, most of the preselected pathways 
were activated in both species. For an organ-specific com-
parison between murine and human PCTS, we used a four 
set Venn diagram (Heberle et al. 2015) with the following 
sets for mouse—significant p value (group A, pathways with 
p value ≤ 0.01) and z-score (group B, activated or inhibited, 
|z-score| ≥ 2), and human—significant p value (group C) and 
z-score (group D) (Fig. 8). The table shows the common 
pathways between the species (ABCD), together with spe-
cies-specific pathways (AB for mouse and CD for human). 
The pathways included in all other groups in Venn diagram 
are provided in File S4. The intersection of the four data 
sets (ABCD in Fig. 8) showed that after PCTS culture, there 
were two common fibrosis pathways: PI3K/AKT signalling 
(liver and kidney) and p38 MAPK signalling (ileum). These 
intersections included also inflammation-related pathways: 
HMGB1 signalling (liver, colon), IL-6 signalling (ileum), 
IL-8 signalling (liver, ileum, colon) and LPS-stimulated 
MAPK signalling (liver). Other common pathways were 
osteoarthritis pathway (kidney, jejunum, ileum and colon), 
NRF-2-mediated oxidative stress response (kidney and 
colon) and PPAR signalling (jejunum and ileum). Regard-
ing species-specific pathways, among murine organs, kid-
ney PCTS displayed most of the differences, which included 
especially fibrosis and inflammation-related pathways. How-
ever, amongst human organs, colon PCTS showed the largest 
number of species-specific pathways (17). Beside the top 
most significantly changed pathways, IPA allows the analysis 
of certain pathways of interest. We showed the changes in 
preselected canonical pathways during PCTS culture that 
had organ and species differences in their regulation.
Discussion
Drug development is a long and expensive process. The 
attrition rates of clinical trials are high although extensive 
advances were made in biomedical research, such as the 
sequencing of the human genome, in silico drug target iden-
tification (Kim et al. 2017) and in vitro assessment of phar-
macological properties (absorption, distribution, metabolism 
and excretion) for new chemical compounds. One of the rea-
sons for this is inadequate preclinical development, which 
includes in vivo, in vitro and ex vivo models that try to 
bridge the gap between the bench and the clinic. To increase 
the success rate of preclinical studies, often hampered by the 
use of animal models lacking translational power, human 
predictive models that are relevant to the research question 
are preferred. An emerging model is represented by preci-
sion-cut tissue slices (PCTS)—a complex ex vivo system 
that preserves organ architecture and cell–cell interactions, 
and allows the use of human tissue. In Part I of this study, we 
described the changes in the transcriptional profiles during 
culture of PCTS obtained from five different healthy organs 
(liver, kidney, jejunum, ileum and colon) and two species 
(mouse and human). Our goal was to identify shared and dif-
ferential regulators that mediate the changes in PCTS during 
culture, as a first step towards the validation of the model.
PCTS preparation and culture entail (cold) ischemia dur-
ing organ collection, mechanical stress due to slicing and 
induction of biological processes as a result of 48-h culture. 
The biological processes induced in cultured PCTS were 
characterized by extensive transcriptional changes reflected 
by the high number of up/downregulated differentially 
expressed genes (DEGs). The regulation profiles of murine 
and human PCTS were driven mostly by organ type and 
time in culture, as shown by PCA (Fig. 2a–d). An interest-
ing difference between the two species was observed in the 
clustering of intestinal samples after culture. Mouse jejunum 
and ileum PCTS clustered together, followed by clustering 
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with colon PCTS. This was expected as jejunum and ileum 
are part of the small intestine and share more features than 
with colon. However, human intestine PCTS showed dis-
tinct clustering, with ileum being more similar to colon than 
jejunum. This may be explained by the cellular composition 
of human intestinal PCTS: their preparation includes the 
removal of the submucosa, muscularis and serosa due to the 
thickness and stiffness of these components. Additionally, 
human jejunum PCTS have the smallest number of changed 
transcripts (hundreds vs. thousands in the other organs), 
indicating that slices of gut mucosa were less affected by 
culture than the other organs. Next, we observed that liver 
and kidney PCTS clustered based on species and not organ 
of origin (Fig. 2e), indicating that although these two organs 
have very different cellular composition, the culture-induced 
processes were species specific.
We investigated the top regulated genes to identify the 
common modulators that drive the changes during cul-
ture in each organ. Although most transcripts were organ 
specific, IL11, MMP3 and MMP10 were commonly pre-
sent among top upregulated DEGs in murine and human 
PCTS. These common markers show that culture produces 
a similar biological response in human and murine PCTS. 
IL-11 is an anti-inflammatory cytokine that has a direct 
effect on macrophages by reducing the production of IL-1β, 
IL-12, nitric oxide and NF-κB (Schwertschlag et al. 1999). 
A: changed (p-value)  
in mouse PCTS 
B: changed (z-score)  
in mouse PCTS 
D: changed (p-value)  
in human PCTS 
C: changed (z-score) 















Fig. 8  Four-set Venn diagram illustrating significantly changed 
selected pathways in murine and human PCTS. Canonical pathways 
in group ABCD are significantly changed (based on p value and 
z-score) during culture pathways in both murine and human PCTS, 
whereas pathways in groups AB and CD are signalling pathways 
significantly changed only in murine PCTS (AB) or only in human 
PCTS (CD). Full list of pathways included in rest of the groups is 
provided in File S4
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Additionally, IL-11 is also involved in the repair response 
by promoting fibroblast activation across different organs 
and species (Schafer et al. 2017). MMPs represent a group 
of enzymes with various functions in biological processes, 
such as inflammation, injury, tissue repair and remodelling 
(Parks et al. 2004); therefore, it was likely to have them in 
the top regulated transcripts. MMP3 (stromelysin-1) and 
MMP10 (stromelysin-2) are secreted by fibroblasts and epi-
thelial cells and have different function in immunity and 
wound healing (Page-McCaw et al. 2007), such as activation 
of IL-1β, MMP9 and certain collagenases (Overall 2002; 
Barksby et al. 2006; Geurts et al. 2008).
To deepen our understanding of the culture-induced con-
dition, we used IPA to decipher the NGS-derived data. IPA 
revealed activation of inflammatory pathways in all organs 
from both species, indicating that culture induces a non-
specific inflammatory response. The most common inflam-
matory pathways across organs and species were IL-6, IL-8 
signalling, high mobility group box 1 (HMGB1) signalling, 
LPS/IL-1-mediated inhibition of RXR function and acute 
phase response signalling. Damaged or dying cells, result-
ing from non-infectious inflammation caused by mechanical 
stress or apoptosis/necrosis, release several damage-asso-
ciated molecular patterns (DAMPs). Representative exam-
ples for DAMPs are mitochondrial DNA, which can lead to 
Toll-like receptor (TLR) 9 stimulation and NF-κB activa-
tion (Zhang et al. 2010), as well as HMGB1, an agonist of 
TLR2 and TLR4 (Sims et al. 2010). The effect of DAMPs 
on macrophages, fibroblasts and endothelial cells will result 
in an immune response characterized by the release of pro-
inflammatory cytokines and chemokines: TNF-α, IL-1α/β, 
IL-6, IL-8 and MCP1, growth factors and ECM-degrading 
enzymes (MMPs) (Zhong et al. 2009; Piccinini and Mid-
wood 2010; Sims et al. 2010; Yu et al. 2019). In our study, 
we observed increased mRNA levels for these pro-inflam-
matory molecules in PCTS during culture; however, it has 
to be further elucidated whether these changes translate into 
changes on protein level.
The increased expression of growth factors and MMPs 
shows that the non-specific defense mechanism is coupled 
with tissue repair processes. Two pathways characterized 
by inflammation and tissue remodelling were enriched in all 
organ PCTS (osteoarthritis pathway and role of osteoblasts, 
osteoclasts and chondrocytes in rheumatoid arthritis) (Gierut 
et al. 2010; Bar-Or et al. 2015). Considering that the studied 
PCTS do not have chondrocytes, osteoclasts or osteoblasts, 
we presume that the fibroblasts and organ-resident immune 
cells are responsible for the transcripts encoding immune 
mediators and metalloproteases (MMPs and ADAMTs) that 
activate these pathways.
On the other hand, culture resulted in the inhibition of 
many canonical pathways, especially those involved in 
biosynthesis, endogenous metabolism and transport. This 
indicates the reduction of the enzymatic and metabolic activ-
ities in PCTS after 48 h. In contrast, previous microarray 
study on human liver PCTS showed that 24-h incubation 
has led only to small changes in the expression of genes 
involved in metabolism and drug transport (Elferink et al. 
2011). Given these points, we consider that most changes 
occur in the second half of the 48-h culture and this has to 
be taken into consideration for studies related to absorption, 
metabolism and excretion in different organs. In particu-
lar, two pathways were commonly inhibited in mouse and 
human organs: PPAR signalling and LXR/RXR activation. 
These are the pathways of nuclear transcription factor recep-
tors: peroxisome proliferator-activated receptor (PPAR), 
liver X receptor (LXR) and retinoid X receptor (RXR) and 
have a role in cellular metabolism. The inhibition of PPAR 
signalling in PCTS might be caused by the high concentra-
tion of glucose in the culture media (25 mM), as similar 
concentrations of glucose were reported to inhibit PPAR 
(Roduit et al. 2000; Cheng et al. 2013; Domínguez-Avila 
et al. 2016) and to lead to several transcriptional changes 
in different organs (Katsoulieris et al. 2016; Boztepe and 
Gulec 2018). However, further functional experiments are 
needed to confirm this hypothesis. The inhibition of PPAR 
signalling leads to a reduction in β-oxidation of fatty acids, 
which can cause an accumulation of fatty acid anions in the 
mitochondria (Ho et al. 2002). As a result, the excess lipids 
inhibit the respiratory complexes of the electron transport 
chain in the mitochondria. This may lead to mitochondrial 
dysfunction, decreased ATP, production of reactive oxygen 
species, inflammation and necrosis (Fromenty and Pessayre 
1995; Wajner and Amaral 2016). The inhibition of PPAR 
signalling was supported by the inhibition of the oxidative 
phosphorylation pathway and activation of NRF-2-mediated 
oxidative stress response. The oxidative phosphorylation 
pathway represents the mitochondrial production of ATP 
from the electron transport system, and its inhibition is 
reflected by a decrease in ATP. In turn, NRF-2-mediated 
oxidative stress response regulates the damage induced by 
oxidative stress (Ma 2013). The second common inhibited 
pathway was LXR/RXR activation, which is also involved 
in lipid metabolism and cholesterol to bile acid catabolism 
(Murthy et al. 2002). This pathway can be inhibited as a 
result of TLR4 activation (Kidani and Bensinger 2014), 
receptor responsive to HMGB1, as previously mentioned. 
These changes show the decline of lipid metabolism during 
PCTS culture.
Activation of NRF-2-mediated oxidative stress response 
pathway and HIF1α signalling in PCTS during culture is 
likely to be associated with exposing the PCTS to high oxy-
gen levels (80%) for 48 h. Given that each slice is about 
ten cell layers thick (approx. 250 µm), high concentration 
of oxygen is necessary to ensure its diffusion from culture 
medium into the deep inner cell layers. It has been shown 
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that oxidative stress plays an important role in fibrosis devel-
opment (Poli 2000; Liu and Gaston Pravia 2010; Lv et al. 
2018). Therefore, induction of oxidative stress and activation 
of the hypoxia-related signalling pathways in PCTS could 
be perceived as an advantage of this ex vivo fibrosis model.
IPA can identify the changes in hundreds of signalling 
pathways, together with the prediction for the direction of 
the downstream effects of different biological processes. 
To better visualize the intricacies in culture of different 
organs PCTS from two species, we focused on a number 
of pathways related to inflammation and fibrosis (Fig. 7), 
as previous studies reported a fibrogenic process during 
PCTS culture (Stribos et al. 2016; Westra et al. 2016; 
Luangmonkong et al. 2017). For each pathway, we showed 
two statistical parameters: the p value and the z-score. 
Both parameters are important to identify the significance 
of the pathways that are driving the biological processes 
and the regulators of interest. We observed significant 
changes in the pathways that drive inflammation and 
fibrosis (Wynn 2008), corroborating the use of PCTS as 
a tool for studying antifibrotic drugs. As an illustration, 
fibroblasts, which upon activation promote intense tis-
sue remodelling, can be induced in our system by several 
pathways and mediators, such as TGFβ–STAT3 pathway 
(Chakraborty et al. 2017), TLR activation (Bhattachar-
yya et al. 2017), chemokines (Sahin and Wasmuth 2013) 
(e.g. gene encoding CCL2 is upregulated during culture in 
both species and all organs except jejunum), and inhibition 
of PPAR signalling (Mann et al. 2010). Additionally, the 
number of fibroblasts can increase as a result of epithelial 
or endothelial cell–mesenchymal transition or activation 
of resident cells, such as hepatic stellate cells in liver. Col-
lectively, focusing the analysis on certain pathways helps 
answering a specific research question, especially when 
more groups are compared (several organs and species).
A major advantage of the PCTS system is the pos-
sibility to use human tissue, eliminating the need for 
mouse–man translation. Our results further emphasize just 
how important the use of human tissue is in pharmacologi-
cal research, as majority of identified DEGs were regu-
lated differently in mouse and human PCTS during cul-
ture. However, preclinical studies performed on laboratory 
animals remain a critical requirement for drug develop-
ment. Therefore, it is crucial to identify both common and 
species-specific regulated canonical pathways in murine 
and human PCTS when investigating a certain pathway 
or pathology. Considering that inflammation and fibrosis 
represent our main interests, we used a 4-set Venn diagram 
(Fig. 8) on selected pathways to identify the shared and 
unique pathways between the two species for each organ 
PCTS. The species-specific pathways give an indication 
of the interspecies differences during culture and can hint 
for which targets the mouse is not the suitable research 
animal. However, we have to take into consideration that 
although culture is a process characterized by an acute 
inflammatory response, infiltrating blood-derived immune 
cells are not present, resulting in a different state than the 
in vivo situation.
One of the disadvantages of PCTS is the limited incu-
bation time due to the loss of tissue viability. The under-
standing of biological processes that occur in PCTS dur-
ing culture gives us the possibility to suggest strategies 
for culture optimization. For instance, the inflammatory 
process in PCTS can be reduced with specific compounds 
that decrease the expression of inflammatory cytokines 
[e.g. prednisolone (Heimburger et al. 2000)] or inhibit 
other factors involved in inflammation [e.g. parthenolide 
inhibits NF-κB (Mathema et al. 2012)]. Of note, the profi-
brotic response observed in slices might diminish upon 
the reduction of inflammatory response, as it is shown 
by Iswandana et al. in murine intestinal PCTS treated 
with rosmarinic acid (Iswandana et  al. 2016). Next, 
reduced lipid metabolism in PCTS during culture might 
be improved if the function of PPARα/δ is restored using 
the agonist elafibranor (Ratziu et al. 2016) that increases 
the β-oxidation of fatty acids. This could be of particular 
interest for liver PCTS as they can be used for preclinical 
studies of non-alcoholic liver disease, a condition charac-
terized by excess lipid accumulation. Next, mitochondrial 
function could be better preserved if the culture media is 
supplemented with compounds that have a positive effect 
on the mitochondria, such as α-lipoic acid (Shay et al. 
2009), l-carnitine (Marcovina et al. 2013) or coenzyme 
Q10 (Orsucci et al. 2011). Lastly, we recommend add-
ing fatty acids and insulin in physiological concentrations 
to the culture media. Fatty acids (e.g. essential linoleic 
and linolenic acids) could stimulate the inhibited path-
ways involved in lipid metabolism, whereas insulin has 
several roles in both carbohydrate and lipid metabolisms 
(Dimitriadis et al. 2011). The suggested methods of cul-
ture optimization might lead to prolonged viability, which 
is a necessary aspect for the validation of the method. It 
has to be noted that these factors, when added to the cul-
ture medium, might influence the expression of genes and 
proteins in PCTS. While the same holds true for the anti-
biotics that were added to Williams’ medium E for cultur-
ing any organ PCTS to prevent microbial contamination, 
there is little evidence that these compounds impact the 
transcription of fibrosis- and inflammation-related genes.
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Part II: Characterization of diseased 
human precision‑cut tissue slices in culture 
and their comparison to healthy control 
slices
Results of Part II
In Part II of this study, we investigated transcriptional 
changes in human PCTS by RNA sequencing. Figure 9a 
shows the general workflow. PCTS obtained from clini-
cally healthy control tissues from patients with various 
underlying diseases will be further addressed as “healthy 
PCTS”. In turn, PCTS obtained from patient diseased 
(fibrotic) tissues will be termed “diseased PCTS”. PCTS 
were prepared from human healthy and diseased tissues, 
namely liver, kidney and ileum, and cultured for 48 h. Of 
note, human lung slices were prepared as described in 
“Methods”, but hereafter were excluded from the down-
stream analyses since diseased lung tissue was available 
only from one patient and no healthy lung tissue could be 
obtained. PCTS were collected at 0 h and 48 h, which were 
then used for viability measurement and deep sequencing. 
Additionally, culture medium after 24 h and 48 h was used 
for secreted cytokines detection. All tissue slices remained 
viable after 48 h culture (Fig. S10a). Although jejunum 
and ileum PCTS had lower RNA quality compared to 
RNAs from liver and kidney PCTS, the overall RNA 
sample quality was good, with mean RNA integrity num-
bers > 7. There was no systematic difference with respect 
to RNA quality between samples from diseased vs. healthy 
PCTS. Interestingly, we observed a slight increase in RNA 
integrity numbers in 48 h samples compared to 0 h sam-
ples (data not shown). Total number of sequenced reads 
varied between 25 and 75 million reads per sample, with 
an average of 61 million reads. Alignment statistics indi-
cated that the data were of high quality and provided suf-
ficient sequencing depth to pursue differential expression 
testing between the experimental groups. For instance, the 
mean rate of unique-mapping exonic reads was 62% per 
sample.
(IIa) Principal component analysis and hierarchical 
clustering in human PCTS
Figure 9b illustrates the results from the PCA derived from 
all genes with scatter plots of the first three components 
PC1, PC2 and PC3 that explained together almost 50% of 
the observed variance in the data. Generally, there was a 
consistent clustering of the samples by tissue type (liver, 
kidney and ileum) in PC1 and by culture time in PC2 (0 h 
and 48 h). Interestingly, these strong tissue- and culture 
time-dependent effects superimposed differences between 
diseased and healthy PCTS since there was no clear sepa-
ration of the samples by pathology in the first three com-
ponents. Percentages of explained variance for each of the 
first three principal components are indicated in Fig. S2c, 
d, which illustrates PCA results for all analysed human 
PCTS (healthy and diseased), including human fibrotic 
lung slices. The latter were excluded from the downstream 
analyses because diseased lung PCTS were obtained from 
only one patient, and healthy control lung tissue was una-
vailable. In line with PCA results, hierarchical clustering 
showed stronger separation of human PCTS by tissue type 
than by pathology or culture time (Fig. 9c, d).
Figure 10 outlines the main directions of performed anal-
yses to aid the general understanding of the study concept.
(IIb) Transcriptomic characterization of human 
diseased PCTS
Genes differentially expressed in diseased PCTS 
during culture
While in Part I we performed a comprehensive transcrip-
tomic analysis of human healthy PCTS, in Part II, we pro-
vide a characterization of human PCTS prepared from dis-
eased tissues by describing the transcripts and pathways that 
were affected by culture (Fig. 11). Generally, we identified 
a large number of differentially expressed genes (DEGs) 
during 48 h culture in all PCTS. In particular, we found 
4808 DEGs in diseased liver PCTS, 3037 DEGs in kidney 
and 1138 DEGs in ileum PCTS (Fig. 11a; volcano plots in 
Fig. S10b). Regarding the directionality of change, we found 
that nearly half of all DEGs were upregulated in kidney and 
ileum PCTS, whereas 64% of transcripts in liver were down-
regulated during culture. The complete lists of DEGs (padj 
value ≤ 0.01 and  log2 (FC) ≥ 1) in diseased PCTS are pro-
vided in File S5.
Top regulated genes and enriched pathways in diseased 
PCTS during culture
To gain better insight into culture-induced changes in dis-
eased PCTS, we identified strongly regulated genes (based 
on fold change) during 48 h of culture, and selected top 
ten genes (up- and downregulated) that showed highest sig-
nificant changes in their expression (Fig. 11b). Transcripts 
were ranked based on the absolute  log2 (FC) values, and 
their descriptions are provided in Table S5. The top ten most 
upregulated genes in diseased PCTS during culture often 
included genes related to inflammation (IL11, SERPINB2, 
IL13RA2, CHI3L1), proteases involved in ECM organiza-
tion (MMP1, MMP3, MMP10) and transporters (SLC7A11, 
CLCA4). MMP1, the gene that encodes interstitial 
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Fig. 9  Study workflow, principal component analyses (PCA) and 
hierarchical clustering in human healthy and diseased PCTS. a Pre-
cision-cut tissue slices (PCTS) were prepared from human healthy 
or diseased liver, kidney and ileum using Krumdieck tissue slicer 
and incubated for 48 h. Samples were collected at 0 h (prior incuba-
tion) and at 48 h for viability measurement, sequencing analysis and 
cytokine release in the culture medium. b Scatter plots of the dimen-
sions PC1 vs. PC2 and PC1 vs. PC3. Samples are coloured by tis-
sue type, shaped by incubation time (0 h or 48 h) and colour filled 
by pathology (healthy or diseased). The heatmap of  log2 (FC) values 
illustrates expression of 18,667 genes (with padj ≤ 0.01) in human 
healthy and diseased PCTS during culture (c) and in pairwise com-
parisons diseased vs. healthy PCTS at 0 h vs. 48 h (d). Independent 
clustering analysis shows stronger separation of samples by tissue 
type (liver, kidney and ileum) than by pathology or culture time (col-
our figure online)
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collagenase, was the only common gene between the top 
ten DEGs in all three organs and it was the highest or second 
highest upregulated gene during 48-h culture. On the other 
hand, genes encoding enzymes (PCK1, HAO2, ACSM2A, 
ACSM2B, NAT8, FMO, GLYAT ), transporters (SLC13A1, 
SLC5A12, SLC34A1) and molecules involved in the immune 
response (CXCR1, FCGR2B, ACKR1) represented the top of 
the downregulated genes.
Next, to assess which biological pathways are involved 
in the culture of diseased PCTS, we performed IPA on all 
DEGs from diseased liver, kidney and ileum PCTS. We 
identified significantly changed canonical pathways (with 
a p value ≤ 0.01) that also showed a direction of change 
based on a z-score ≥ 2 (predictor of activation) or ≤ − 2 
(predictor of inhibition). The top five most activated and 
the top five most inhibited canonical pathways in diseased 
human PCTS during culture are displayed in Fig. 11c. Com-
plete lists of significantly changed pathways (provided in 
Fig. S11) revealed that osteoarthritis pathway was activated 
in all diseased PCTS. Despite its name, osteoarthritis path-
way involves numerous fibrosis- and inflammation-related 
genes (see “Discussion” of Part II). Three pathways—actin 
nucleation by ARP–WASP complex, integrin signalling 
and ephrin receptor signalling—were commonly activated 
in liver and kidney PCTS, whereas acute phase response 
signalling was present in both kidney and ileum PCTS. 
Moreover, diseased kidney and ileum PCTS shared culture-
induced activation of other four pathways that were related 
to cholesterol biosynthesis. Among commonly inhibited 
pathways, LXR/RXR activation was found in all cultured 
organ PCTS. Furthermore, after 48 h in culture several 
metabolism-related pathways were inhibited (for example, 
nicotine, melatonin, serotonin and tryptophan degradation) 
in liver and kidney PCTS.
Regulation of fibrosis‑ and inflammation‑associated 
pathways in diseased PCTS during culture
Culturing of healthy slices results in the development of 
spontaneous (i.e. not exogenously induced) fibrogenic and 
inflammatory responses; however, little is known about the 
impact of culture on slices prepared from diseased tissues. 
Considering that the Ingenuity Pathways Knowledge Base 
(IPKB) contains information on more than 330 biochemi-
cal pathways, we selected several canonical pathways 
a priori, with a focus on fibrosis and inflammation, and 
investigated their regulation in diseased PCTS. Figure 12 
illustrates the culture-induced changes in the selected 
pathways in diseased PCTS (information on key signal-
ling molecules involved in each pathway is provided in 
File S3). Fibrosis-associated signalling pathways showed 
significant changes in all PCTS, especially in liver PCTS, 
where 12 out of 17 canonical pathways were altered at 
48 h. Kidney and ileum showed less changes: only three 
pathways were regulated significantly different at 48 h 
compared to 0 h. The direction of change (indicated by 
the z-score) showed activation of PI3K/AKT signalling 
in liver and kidney, whereas this pathway was inhibited in 
ileum PCTS. Additionally, liver PCTS displayed activation 
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Fig. 10  Visual summary of the study, capturing the concept and 
main lines of performed analysis. Human healthy PCTS (a) undergo 
substantial transcriptional changes during 48-h culture and acquire 
profile A’, with thousands of genes differentially expressed between 
A and A’. These culture-induced DEGs (DEGs A–A’) and involved 
canonical pathways are described in detail in Part I. Similarly, dis-
eased PCTS (b) are also profoundly affected by culture, as they dis-
play thousands of DEGs (DEGs B–B’), and develop 48-h transcrip-
tional profile B’. We compared the impact of culture on healthy and 
diseased PCTS by uncovering differences and similarities between 
data on DEGs A–A’ (top transcripts and canonical pathways) pre-
sented in Part I and DEGs B–B’ described in Part II. We also deter-
mined common and unique transcripts between culture-induced 
DEGs in healthy slices (A–A’) and in diseased slices (B–B’). Based 
on common DEGs A–A’ vs. B–B’, we identified biological pathways 
commonly changed in healthy and diseased PCTS
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c Canonical Pathway z-score -log(p-value) Size Downregulated (%) Upregulated (%) Overlap (%)
PI3K/AKT Signaling 3,02 3,19 131 20 56 76
LPS/IL-1 Mediated Inhibition of RXR Function 2,97 23,10 222 56 27 84
Ephrin Receptor Signaling 2,72 5,18 179 26 54 80
Actin Nucleation by ARP-WASP Complex 2,71 5,11 62 16 60 76
p53 Signaling 2,35 4,36 111 32 47 79
Actin Nucleation by ARP-WASP Complex 3,50 3,12 62 23 53 76
Osteoarthritis Pathway 3,33 3,74 212 31 49 80
Integrin Signaling 2,60 4,04 219 26 48 75
Superpathway of Cholesterol Biosynthesis 2,33 2,67 28 21 64 89
Acute Phase Response Signaling 2,27 2,89 176 31 52 82
Osteoarthritis Pathway 3,40 5,94 212 26 54 80
Superpathway of Cholesterol Biosynthesis 3,32 7,81 28 11 79 89
NRF2-mediated Oxidative Stress Response 2,71 3,16 199 24 50 74
Colorectal Cancer Metastasis Signaling 2,60 3,66 254 26 52 78
Cholesterol Biosynthesis I 2,45 4,97 13 8 92 100
Nicotine Degradation II -5,66 9,72 65 65 11 75
Melatonin Degradation I -5,48 8,31 65 68 11 78
Nicotine Degradation III -5,20 8,06 56 64 13 77
LXR/RXR Activation -5,17 22,50 121 67 27 94
Superpathway of Melatonin Degradation -5,15 10,10 70 67 13 80
PPAR Signaling -2,98 2,24 101 20 54 74
iCOS-iCOSL Signaling in T Helper Cells -2,52 2,17 123 46 28 75
Tryptophan Degradation III (Eukaryotic) (*) -2,12 2,42 25 60 36 96
LXR/RXR Activation (*) -2,07 2,26 121 43 50 94
Serotonin Degradation (*) -2,00 2,10 77 61 16 77
Cyclins and Cell Cycle Regulation -2,83 2,47 81 41 36 77
LXR/RXR Activation (*) -2,71 3,45 121 31 62 94
Antioxidant Action of Vitamin C -2,65 2,94 108 31 47 81
Estrogen-mediated S-phase Entry -2,65 3,94 26 62 19 81






























Fig. 11  Characterization of human diseased PCTS. a Total number 
of differentially expressed genes (DEGs), upregulated and downreg-
ulated, in human diseased PCTS. DEGs were defined as genes with 
 log2 (FC) ≥ 1 and padj value ≤ 0.01. Full lists of identified DEGs are 
provided in File S5. b Top ten regulated DEGs based on the  log2 (FC) 
values. Gene descriptions are provided in Table S5. c Top five canon-
ical pathways identified by IPA. Only pathways with p value ≤ 0.01 
and a z-score ≥ 2 (predictor of activation) or ≤ − 2 (predictor of inhi-
bition) were included. Pathway size (i.e. total number of genes in a 
pathway), percentage of significantly downregulated (green bars) and 
upregulated (red bars) genes in a given pathway, and percentage of 
overlap with the dataset (grey bars) are indicated for each pathway. 
Full lists of significantly changed pathways in PCTS from each organ 
are provided in Fig. S11 (colour figure online)
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signalling was activated in kidney PCTS. Furthermore, 
two selected canonical pathways related to ECM organi-
zation, namely inhibition of matrix metalloproteases and 
integrin signalling, showed significant culture-induced 
changes in PCTS from all diseased organs. Activation was 
predicted only for integrin signalling in liver and kidney.
Similarly, inflammation-associated pathways also 
showed significant changes in all diseased PCTS after 
48 h culture: out of 21 selected pathways, culture altered 
13 pathways in liver PCTS, 11 in kidney PCTS and 8 in 
ileum PCTS. In addition, seven of these changed pathways 
were affected by culture in all three organs and included 
HMGB1 signalling, IL-6, IL-8, IL-10, IL-17 signalling, 
IL-17A signalling in fibroblasts and LPS/IL-1-mediated 
inhibition of RXR function. The only predicted direction 
of change was the activation of HMGB1 signalling and 
LPS/IL-1-mediated inhibition of RXR function in liver 
PCTS, interferon signalling in kidney PCTS, and IL-6 sig-
nalling in ileum PCTS.
Overall, culture induced significant changes in fibro-
sis- and inflammation-related canonical pathways in all 
diseased PCTS. Most of the culture effects were found 
in liver, while kidney and ileum PCTS were affected to a 
lesser extent.
(IIc) Comparative analysis of human diseased vs. 
healthy PCTS
Genes differentially expressed in diseased and healthy 
PCTS before and after culture
As a part of the comparative analysis, we investigated 
the transcripts and pathways differentially regulated in 
diseased vs. healthy PCTS that were directly affected by 
pathology and/or culture. Comparison of the baseline 
transcription profiles (at 0 h) in human PCTS (Fig. 13a; 
volcano plots in Fig. S10c) showed that healthy and dis-
eased tissues had major differences prior to culturing, as 
illustrated by a large number of DEGs in liver and kid-
ney PCTS (1500 and 2016 DEGs, respectively). In con-
trast, only eight genes were differentially expressed at 0 h 
in diseased ileum PCTS compared to healthy slices. By 
48 h of culture, the number of DEGs between diseased 
and healthy tissues dramatically decreased in all organs, 
reaching 91% reduction in DEGs in liver, 98% in kidney 
and 100% in ileum (Fig. 13a; volcano plots in Fig. S10d). 
Closer examination of these changes showed that in (dis-
eased vs. healthy) liver PCTS, 59% (83 of 141) of DEGs 
at 48 h were also differentially expressed at 0 h with a con-
sistent direction of regulation (i.e. up- or downregulation). 
The remaining proportion of regulated transcripts (41%) in 
diseased vs. healthy liver PCTS was exclusively observed 
after 48 h culture. In kidney, only 27% (10 of 37) of genes 
differentially expressed in diseased vs. healthy PCTS at 
48 h were also among DEGs at 0 h, while 73% of tran-
scripts were specifically induced by culture. Furthermore, 
we identified DEGs that showed the strongest differential 
regulation between healthy and diseased PCTS prepared 
from the three organs before culture (Fig. 13b) and after 
48-h culture (Fig. 13c). The results showed that there were 
no common top up- and downregulated DEGs between 
0 h and 48 h in any organ PCTS. Among the most regu-
lated transcripts, we often encountered genes encoding 
enzymes, transporters and inflammatory molecules. Addi-
tionally, top ten up- and down-regulated DEGs included 
novel uncharacterized transcripts. The corresponding 
lists of all DEGs are provided in File S6, and the detailed 
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Fig. 12  Regulation of preselected pathways in human diseased PCTS 
during 48-h culture. Purple colour indicates a significant pathway 
change based on a p value ≤ 0.01, whereas predicted pathway activa-
tion (A) or inhibition (I) is indicated by a z-score, if available. Sig-
nalling molecules involved in each preselected pathway are shown in 
File S3 (colour figure online)





























Fig. 13  Comparative analysis of human diseased and healthy PCTS 
in their baseline expression profiles (0 h) and profiles after 48-h cul-
ture. a Total number of genes, upregulated and downregulated, that 
were differentially expressed between diseased and healthy PCTS at 
0 h or 48 h. DEGs were defined as genes with  log2 (FC) ≥ 1 and padj 
value ≤ 0.01. Numbers in brackets indicate the percentage of DEGs at 
48  h that were also DEGs at 0  h. Top ten regulated genes that are 
differentially expressed between diseased and healthy PCTS at base-
line (b) and after 48-h culture (c). Significantly upregulated DEGs 
are displayed in red colour and downregulated—in green. Genes were 
selected based on the  log2 (FC) values. Full lists of identified DEGs 
are provided in File S7 (colour figure online)
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DEGs and enriched canonical pathways in human PCTS 
induced by pathology
We continued the analysis by elucidating the DEGs and 
enriched canonical pathways that were induced in human 
PCTS by pathology. First, we performed pathway analy-
sis on all genes differentially expressed in diseased vs. 
healthy PCTS prior to culture (as listed in File S6). The 
results showed that numerous pathology-driven signalling 
pathways were regulated in liver and kidney PCTS, but 
not ileum (due to low number of DEGs) (File S7). As 
an example, before culturing, diseased and healthy liver 
PCTS showed dramatic difference in regulation of canoni-
cal pathway hepatic fibrosis/hepatic stellate cell activation 
with p value ≤ 10−9. Next, Venn diagrams illustrated the 
number of differentially expressed genes in diseased vs. 
healthy PCTS exclusively before and after culture, as well 
as numbers of DEGs that were present at both time points 
(Fig. 14a). Tables with the common and unique genes for 
each organ can be found in File S8. Each list was ranked 
by a differential gene expression score (DGE score), which 
represents the product of |log2 (FC)| and – log10 (p adjusted 
value). DEGs unique to diseased vs. healthy PCTS at 
baseline (0 h) represent the set of transcripts that were 
induced specifically by pathology. DEGs unique to dis-
eased vs. healthy cultured PCTS (48 h) are the genes that 
were altered by both pathology and culture. Additionally, 
the intersection of the two groups represents the common 
DEGs that were affected by pathology, but not by culture. 
Next, we performed IPA on DEGs from the Venn diagram 
intersections to assess the canonical pathways induced 
by the pathology. In agreement with the small number of 
common DEGs, there were only five canonical pathways 
significantly enriched in liver PCTS (Fig. 14b). None of 
these pathways showed a predicted direction of change. 
Additionally, we determined signalling pathways that were 
differentially expressed by diseased and healthy liver and 
kidney PCTS after 48 h of culture (File S7). The major dif-
ferences between healthy and diseased PCTS after culture 




























Canonical Pathway z-score -log(p-value) Size Regulated (%) Overlap (%)
VDR/RXR Activation NA 2,88 78 4 18
GABA Receptor Signaling NA 2,63 95 3 24
GP6 Signaling Pathway NA 2,21 134 2 31
Pregnenolone Biosynthesis NA 2,11 12 8 58

















Fig. 14  Comparative analysis of baseline expression profiles (0  h) 
and profiles after 48-h culture in human diseased vs. healthy PCTS. 
a Venn diagrams illustrating the number of unique and overlapping 
genes upregulated (in red) and downregulated (in green) at 0  h vs. 
48  h in human diseased vs. healthy PCTS. Lists of corresponding 
DEGs can be found in File S9. b Top canonical pathways identified 
by IPA based on common DEGs shown in Venn diagrams. Only liver 
PCTS had enough common DEGs at baseline vs. 48 h to perform IPA 
(colour figure online)
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Differences in regulation of fibrosis‑ 
and inflammation‑associated pathways in diseased vs. 
healthy PCTS before and after culture
To advance our understanding of fibrosis and inflammation-
associated processes in human PCTS, we investigated dif-
ferences in the regulation of 40 selected canonical pathways 
between healthy and diseased PCTS prior and after culture 
(Fig. 15). In accordance with the reduction in total numbers 
of DEGs after 48 h, diseased vs. healthy slices showed more 
differences in regulated canonical pathways at baseline than 
after culture. In particular, diseased liver PCTS at 0 h showed 
significant regulation for 16 out of 40 selected pathways 
(based on both p value and z-score) compared to healthy liver 
PCTS. In case of kidney PCTS, 17 out of 40 pathways were 
significantly different due to pathology, and no differences in 
pathways were observed in ileum PCTS. After 48-h culture, 
only two pathways were significantly different in diseased liver 
PCTS compared to healthy slices, whereas no difference in 
pathway regulation was observed in diseased vs. healthy kid-
ney and ileum PCTS.
Fig. 15  Differential regula-
tion of preselected pathways 
between healthy and diseased 
human PCTS at baseline (0 h) 
and after 48-h culture. Purple 
colour indicates a significant 
pathway change based on a p 
value ≤ 0.01, whereas predicted 
pathway activation (A) or 
inhibition (I) is indicated by a 
z-score, if available. Signalling 
molecules involved in each pre-
selected pathway are shown in 























































Inhibition of Matrix Metalloproteases
Integrin Signaling A
Chemokine Signaling










IL-12 Signaling and Production in Macrophages
IL-15 Signaling
IL-17 Signaling
IL-17A Signaling in Fibroblasts
iNOS Signaling
Interferon Signaling A
LPS/IL-1 Mediated Inhibition of RXR Function
T Cell Receptor Signaling

















































































Canonical Pathway z-score -log(p-value) Size Regulated (%) Overlap (%)
Integrin Signaling 4,81 7,20 219 13 26
Signaling by Rho Family GTPases 4,80 4,96 252 11 22
IL-8 Signaling 4,60 6,79 203 13 28
Phospholipase C Signaling 4,26 3,89 244 10 22
Ephrin Receptor Signaling 4,15 8,58 179 16 28
RhoGDI Signaling -4,80 8,06 177 15 24
PTEN Signaling -2,67 3,55 125 12 21
Osteoarthritis Pathway 3,90 6,85 212 10 27
IL-8 Signaling 3,77 5,33 203 9 28
Integrin Signaling 3,64 3,81 219 8 26
ILK Signaling 3,61 2,87 197 7 24
Neuroinflammation Signaling Pathway 3,50 2,16 311 5 25
RhoGDI Signaling -3,46 2,37 177 7 24
PPAR Signaling -2,83 2,13 101 8 21
Osteoarthritis Pathway 3,64 9,07 212 8 27
IL-8 Signaling 3,61 6,07 203 7 28
Colorectal Cancer Metastasis Signaling 3,46 3,68 254 5 21
IL-6 Signaling 3,16 4,79 134 7 24
Endothelin-1 Signaling 3,00 2,81 196 5 24
PPAR Signaling -2,65 3,32 101 7 21
LXR/RXR Activation -2,65 4,36 121 7 54
Antioxidant Action of Vitamin C -2,45 5,63 108 9 27
LPS/IL-1 Mediated Inhibition of RXR Function 3,67 21,60 222 23 39
LXR/RXR Activation -4,74 30,30 121 39 54
Nicotine Degradation II -4,47 11,10 65 31 43
Superpathway of Melatonin Degradation -4,36 9,49 70 27 39
Melatonin Degradation I -4,24 9,18 65 28 37
cAMP-mediated signaling -4,15 2,93 228 10 21
Neuroinflammation Signaling Pathway -4,80 3,41 311 9 25
Dendritic Cell Maturation -4,36 3,19 194 10 24
PKCÎ¸ Signaling in T Lymphocytes -3,87 3,61 165 11 19
Role of NFAT in Regulation of the Immune Response -3,77 3,24 192 10 19
ILK Signaling -3,77 2,71 197 9 24
Mitotic Roles of Polo-Like Kinase -2,45 4,49 66 11 27
Cyclins and Cell Cycle Regulation -2,24 3,07 81 7 30





















































Fig. 16  Comparative analysis of culture-induced changes in expres-
sion profiles between healthy and diseased PCTS. a Venn diagrams 
illustrating the number of unique and overlapping genes (DEGs) 
upregulated (in red) and downregulated (in green) in human healthy 
and diseased PCTS during 48-h culture. Total numbers of culture-
induced DEGs in PCTS from diseased liver, kidney and ileum are 
illustrated in Fig. 11a, while total numbers of DEGs found in healthy 
PCTS are depicted in Fig. 3b in Part I. Complete lists of DEGs are 
provided in File S6. b Top canonical pathways enriched from com-
mon culture-induced DEGs present in both healthy and diseased 
PCTS. Only pathways with p value ≤ 0.01 and a z-score ≥ 2 (predic-
tor of activation) or ≤ − 2 (predictor of inhibition) were included. 
Pathway size (i.e. total number of genes in a pathway), percentage of 
significantly downregulated (green bars) and upregulated (red bars) 
genes in a given pathway, and percentage of overlap with the dataset 
(grey bars) are indicated for each pathway (colour figure online)
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DEGs and enriched canonical pathways induced in healthy 
and diseased PCTS during culture
Considering that healthy (Part I) and diseased PCTS devel-
oped substantial transcriptional alterations during 48 h cul-
ture, we determined genes and canonical pathways that are 
culture affected in both healthy and diseased tissues. First, 
we identified common and unique culture-induced DEGs 
(up- and down-regulated) in healthy and diseased PCTS 
(Fig. 16a). To this end, we compared all DEGs found in dis-
eased PCTS (Fig. 16a) to all DEGs reported in healthy PCTS 
(Part I, Fig. 3b). Unique DEGs were affected by culture and 
pathology (i.e. expressed only in healthy or diseased PCTS), 
whereas DEGs in intersections were transcripts affected by 
culture. The complete lists of all DEGs included in Venn 
diagrams are shown in File S9. As a next step of the analy-
sis, we performed IPA on overlapping gene sets. The most 
significant canonical pathways enriched from these gene 
sets are summarized in Fig. 16b. Culture-induced pathways 
across healthy and diseased PCTS included activated path-
ways, such as osteoarthritis pathway, IL-8 signalling and 
integrin signalling, and inhibited pathways, such as LXR/
RXR activation, PPAR signalling and RhoGDI signalling. 
Of note, canonical pathways enriched from downregulated 
DEGs were more organ specific, and were related to metabo-
lism, inflammation and cell cycle regulation.
Cytokine release profiles of human healthy and diseased 
PCTS
As part of cellular mechanisms of fibrosis, damaged epi-
thelial cells and (resident) immune cells secrete vari-
ous cytokines that drive the inflammatory and fibrogenic 
responses (Wynn 2004). Along with the transcriptional 
changes, we assessed PCTS cytokine release profiles during 
48 h to examine whether diseased and healthy PCTS display 
differences in production of inflammatory mediators. To this 
end, we analysed the culture medium for the presence of 42 
cytokines and cytokine modulators (all measurements are 
included in File S10). We selected 29 cytokines for further 
analysis based on two criteria: (1) minimum concentration of 
20 pg/mL detected in the medium in at least one experimen-
tal condition, and (2) significant regulation on gene expres-
sion level. The independent hierarchical clustering separated 
diseased liver and kidney PCTS from the corresponding 
healthy slices, suggesting considerable pathology-driven 
differences in cytokine release (Fig. 17a). In turn, diseased 
and healthy ileum PCTS had very close resemblance in their 
cytokine release profiles, which distinguished them from the 
other two organs. PCTS displayed few characteristic fea-
tures in cytokine release. For instance, healthy liver PCTS 
showed higher production of IL-7 and SAA1, compared to 
diseased liver and other organ PCTS. In turn, diseased liver 
PCTS produced more IL-16 and HGF than healthy slices. 
Healthy and diseased kidney PCTS released more MCP-1 
and OPN compared to other slices. Furthermore, diseased 
kidney showed the highest release of most tested analytes 
among all human PCTS. Lastly, healthy and diseased ileum 
highly secreted IL-12A, IL-17A, MMP2, MMP3, IFNG and 
GM-SCF.
Next, to address the question whether gene expression 
of selected cytokines reflected their protein levels, we per-
formed correlation analysis (Fig. 17b). In general, in all 
organ PCTS, high gene expression of inflammatory media-
tors was positively associated (approximately 45–70%) with 
high level of their protein release. Interestingly, all human 
healthy and diseased PCTS showed both high expression 
and secretion of TIMP1, a cytokine with enzymatic activity 
that inhibits ECM degradation by MMPs. Additionally, all 
kidney PCTS and diseased liver slices showed high gene and 
protein expression of MCP-1 (encoded by CCL2) and OPN 
(encoded by SPP1) during culture, when taking into account 
both MSD and RNA-Seq results. Both MCP-1 (monocyte 
chemoattractant protein 1) and OPN (osteopontin) are 
actively involved in the inflammatory response and fibro-
genesis by promoting the recruitment of immune cells to the 
site of tissue injury. Organ differences in cytokine regulation 
are also highlighted by the correlation study, as liver PCTS 
highly expressed and secreted SAA1, while MMP2 and 
MMP3 were characteristic for ileum PCTS. SAA1, serum 
amyloid A1, is a major acute-phase response protein that is 
predominantly secreted by hepatocytes. Similar to MCP-1 
and OPN, SAA1 induces chemotaxis in inflammatory cells 
and their cytokine/chemokine production (Sack 2018). This 
pro-inflammatory mediator has also been shown to upregu-
late ECM-degrading enzymes (MMPs) (Sack 2018). Taken 
together, these results showed that pre-existing pathology 
accentuates cytokine production in human PCTS, with 
positive association between protein and mRNA levels, 
especially for cytokines with relatively high levels of gene 
expression and gene protein product release.
Discussion
Among different in vitro/ex vivo preparations of human 
organs, precision-cut tissue slices (PCTS) represent a 
system with particularly high similarity to the originating 
organ. Among the wide range of applications, the PCTS 
model is gaining its value in studying the mechanisms of 
organ fibrosis and antifibrotic compounds. However, the 
molecular processes that occur in PCTS during culture 
remain largely uncharacterized, preventing the adoption 
of PCTS model in preclinical research to its full potential. 
In this study, we sequenced total RNA of PCTS prepared 
from human healthy and diseased liver, kidney and ileum 
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with the aim to elucidate culture-driven transcriptional 
changes, especially those related to inflammation and 
fibrosis. We characterized diseased PCTS in culture by 
describing main differentially expressed transcripts and 
culture-affected biological pathways. Furthermore, we 
demonstrated that culture impacts healthy and diseased 
tissue slices in a universal way, converging them to a com-
mon, inflammation- and fibrosis-driven condition with 
limited transcriptional differences between healthy and 
diseased PCTS, while the underlying pathology endures.
Culture impacts human PCTS from healthy 
and diseased tissues in a universal way, triggering 
mechanisms of wound healing and fibrosis
Preparation of the tissue slices causes significant injury as 
a result of a combination of cold ischemia prior to slicing 
and mechanical trauma during slicing, both of which are 
inevitable. It has to be noted that all human tissues—clini-
cally healthy and diseased—were obtained from patients 









Fig. 17  Cytokine release by human healthy and diseased PCTS after 
48  h in culture. a Heatmap of the absolute concentrations (pg/mL) 
illustrates cytokine release profile of human healthy and diseased 
PCTS. PCTS from liver, kidney and ileum were incubated for 48 h, 
culture medium was collected after 24 h and 48 h and tested for the 
presence of selected cytokines using Meso Scale Discovery (MSD) 
multiplex assay. For each cytokine, concentrations measured at 24 h 
and 48  h were normalized to the negative control (i.e. freshly pre-
pared medium) and summed to determine total cytokine concentra-
tion at the end of culture period. b Correlation analysis of the rela-
tionship between cytokine protein expression (as measured by MSD) 
and gene expression (as measured by NGS/RNA-Seq). Each dot rep-
resents one cytokine; green colour codes healthy PCTS, while blue 
colour codes diseased PCTS. Highly expressed cytokines (i.e. > 100 
RPKM on gene level and > 1000  pg/mL on protein level) are anno-
tated
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or bleeding and underwent surgical procedure. These might 
influence the initial transcriptional background of human tis-
sues, including healthy control samples, since it was shown 
that surgical intervention causes an acute-phase response 
and increase in cytokine production (de Jong et al. 2004).
It is well recognized that in response to the injury, various 
organs share common mechanisms associated with wound 
healing and fibrosis (Zeisberg and Kalluri 2013; Rockey 
et al. 2015). Culturing of the slices prompts the progression 
of fibrosis by driving an environment of sustained injury. 
Indeed, human PCTS of different organ of origin and pre-
existing pathology showed similarities in the way that cul-
ture affected their transcriptional profiles, supporting that 
culture triggers common mechanisms of wound healing and 
fibrosis.
Our Part I study showed that human PCTS prepared from 
healthy tissues undergo substantial transcriptional changes 
during culture, with thousands of differentially expressed 
genes. Here we show that culture also induced pronounced 
transcriptional changes in PCTS from diseased tissues, 
counted in thousands of genes as well, pushing the dis-
eased slices beyond their initial pathology. The comparison 
of these changes in healthy and diseased PCTS (Fig. 10: 
DEGs A–A’ vs. DEGs B–B’) delineated universal impact of 
culture on human tissues. We demonstrated that all human 
PCTS, regardless the originating organ or pre-existing 
pathology, displayed, on one hand, culture-induced inflam-
matory response and matrix remodelling, and on the other 
hand, dysregulated enzymatic and transporter activity, as 
illustrated by identified common transcripts and biological 
pathways.
For instance, transcripts encoding inflammatory cytokine 
IL-11 and ECM-degrading enzymes MMP1, MMP3 and 
MMP10 were found among the DEGs with the highest fold 
change in all diseased PCTS (Fig. 11b)—the same tran-
scripts that were strongly upregulated across healthy human 
PCTS, as reported in Part I of this study. The homogeneity 
in the effects of culture is further illustrated by the fact that 
diseased liver, kidney and ileum PCTS shared five out of 
ten top upregulated genes during culture with the respective 
healthy slices, while the majority of other 5 genes was also 
shared but outside the top 10 list (instead, these were shared 
within top 100). As an example, SERPINB2, encoding plas-
minogen activator inhibitor type 2 (PAI-2), was identified 
as the gene with the highest fold change among all DEGs 
in healthy and diseased kidney PCTS (i.e. ranked first in 
the top ten upregulated genes), and it was also significantly 
upregulated during culture in other organ PCTS, only with 
a smaller fold change. PAI-2 is a stress protein expressed 
in activated monocytes and macrophages and is highly 
inducible in fibroblasts and endothelial cells (Kruithof et al. 
1995; Medcalf and Stasinopoulos 2005). PAI-2 transcrip-
tion is stimulated by a variety of inflammatory mediators, 
suggesting its biological role in the regulation of inflamma-
tion and wound healing (Medcalf and Stasinopoulos 2005). 
Additionally, most of the common DEGs with the highest 
differential gene expression score (DGE score), affected by 
culture in both healthy and diseased PCTS, were also related 
to ECM organisation (Fig. 13a, File S7), supporting the idea 
that culture augments fibrosis-associated tissue remodelling 
in healthy and diseased slices alike. As an example, healthy 
and diseased liver PCTS showed significant upregulation 
after the culture of NID2, LAMA4 and ITGA2 that encode 
the ECM structural constituents nidogen, laminin and inte-
grin, respectively. Additionally, healthy and diseased liver 
PCTS highly expressed latexin (encoded by LXN), which 
serves as a marker of portal myofibroblasts (Lemoinne 
et al. 2013), and epoxide hydrolase 4 (encoded by EPHX4), 
which reduces bioactivity of fatty acids (Lord et al. 2013). 
The latter is in accordance with the observed inhibition of 
LXR/RXR activation and fatty acid beta-oxidation path-
ways. Similarly, culture enhanced upregulation of ZPLD1, 
ITGB3 and ITGB6 in healthy and diseased kidney slices. 
While ITGB3 and ITGB6 encode integrins that bind to ECM 
proteins, ZPLD encodes ECM glycoprotein zona pellucida-
like domain-containing 1 although little is known about its 
function (Hynes and Naba 2012). Furthermore, as found 
previously, both healthy and diseased ileum PCTS highly 
express ECM-related genes MMP1 and MMP3. Culturing 
of the slices was also associated with altered enzymatic and 
transporter activity, as top downregulated genes in healthy 
and diseased PCTS encoded various enzymes and transport-
ers although these had more diversity between the organs 
(Figs. 11b and 4b in Part I).
The commonalities in culture-induced transcripts trans-
lated into commonly regulated biological pathways in 
healthy and diseased PCTS. Cross-comparison of identi-
fied culture-induced biological pathways in diseased PCTS 
(Fig. 11c) with the data on human healthy PCTS reported in 
Part I, revealed that diseased liver, kidney and ileum PCTS 
shared 90%, 35% and 60% of activated by culture pathways 
with corresponding healthy organ slices, respectively. In 
turn, 60%, 60% and 20% of inhibited pathways were the 
same between healthy and diseased liver, kidney and ileum 
PCTS, respectively. The homogeneity of culture effects on 
tissue slices was further supported by the fact that all human 
PCTS, regardless of the originating organ or pre-existing 
pathology, showed consistent significant activation of osteo-
arthritis pathway and inhibition of LXR/RXR activation dur-
ing culture. The implications of the latter were discussed in 
detail in Part I; therefore, here we will address the former. As 
a fibrosis-associated disease, osteoarthritis is characterized 
by extensive structural changes in ECM under inflamma-
tory conditions that ultimately leads to joint stiffness and 
disability (Hill et al. 2007; Remst et al. 2015). According to 
IPA, osteoarthritis pathway involves over 200 transcripts, 
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encoding ECM structural components (e.g. collagens, inte-
grins, fibronectin and decorin), ECM remodelling enzymes 
(MMPs and TIMPs), inflammatory molecules (e.g. IL-1B, 
CXCL8, TNF, TLR2 and TLR4, to name a few), as well as 
downstream molecules of TGF, PDGF, VEGF, FGF, WNT 
and SHH signalling cascades, among others. The fact that 
osteoarthritis pathway is significantly activated in all human 
PCTS at 48 h and in murine PCTS (as found in Part I) sug-
gests that culture sustains pro-inflammatory and profibrotic 
environment.
Among other shared canonical pathways, actin nuclea-
tion by ARP–WASP complex and ephrin receptor signal-
ling were activated by culture in liver and kidney PCTS, 
both healthy and diseased. Actin nucleation by ARP–WASP 
complex is known to promote cell migration (Kaverina et al. 
2003; Yamaguchi et al. 2005), a phenomenon that plays an 
important role in tissue fibrosis, as migration of fibroblasts 
toward fibrotic lesions is essential for pathological matrix 
deposition (Tschumperlin 2013). In turn, the Eph receptors 
and their ligands ephrins play an important role in injury (in 
particular, wound healing and ischemia–reperfusion injury) 
and inflammation (Coulthard et al. 2012). It has been shown 
that Eph receptor EPHB2 is overexpressed in hepatocellu-
lar carcinoma, end stage of liver fibrosis/cirrhosis and in 
other fibrotic diseases (Hafner 2004; Mimche et al. 2018). At 
last, we demonstrated that common DEGs after 48-h culture 
between healthy and diseased PCTS additionally enriched 
IL-8 signalling and integrin signalling (Fig. 11b), support-
ing our observation that culture induces inflammation- and 
fibrosis-associated biological processes in tissue slices. 
Interestingly, part of the analysis that was dedicated to the 
regulation of selected pathways in diseased PCTS showed 
that even though culture augmented transcriptional changes 
in inflammatory and fibrosis pathways in all organ PCTS, 
diseased liver PCTS displayed the most pronounced changes 
(Fig. 12). Taken together, these observations reinforce the 
use of human PCTS as an ex vivo fibrosis model.
Organ‑ and pathology‑specificity in the effect of culture
Despite the described uniformity in the effects of culture on 
tissue slices, our comprehensive sequencing data allowed to 
detect organ-specific differences in transcriptional changes 
between liver, kidney and ileum PCTS. We chose to exem-
plify such differences with intestinal PCTS although similar 
critical examination can be done for liver and kidney PCTS.
On the gene expression level, we identified several tran-
scripts—DUOX2, DUOXA2, CEMIP and CHI3L1—that 
were strongly upregulated during culture only in human 
intestinal PCTS, regardless of the pre-existing pathology. 
Dual oxidase 2, encoded by DUOX2, is an intestinal epithe-
lium-specific NADPH oxidase that plays a critical role in the 
innate defense response against the microbiota by generating 
reactive oxygen species (El Hassani et al. 2005; Grasberger 
et al. 2015). It has been shown that both DUOX2 and its 
maturation factor DUOXA2 are upregulated in association 
with chronic inflammatory disorders of the gastrointestinal 
tract, such as Crohn’s disease (CD), ulcerative colitis (UC) 
and UC-associated colorectal cancer (MacFie et al. 2014; 
Haberman et al. 2014). In turn, expression of endosomal 
cell migration-inducing and hyaluronan-binding protein 
(CEMIP) is highly elevated in colorectal cancer although 
its role remains unclear (Fink et al. 2015). Gene CHI3L1 
encodes chitinase-3-like protein 1 (also known as BRP-39), 
a marker for late stages of macrophage differentiation (Rehli 
et al. 2003). Dysregulation of BRP-39 is often associated 
with human diseases characterized by acute or chronic 
inflammation and fibrosis (Lee et al. 2011).
Similarly, organ-specific differences can be traced on the 
pathway level. For instance, both healthy and diseased ileum 
PCTS displayed (almost exclusively) significant activation of 
colorectal cancer metastasis signalling and IL-6 signalling. 
Closer examination of the activated biological pathways also 
suggests pathology-specific differences in the effects of cul-
ture on human PCTS. We found that PCTS from healthy tis-
sues seem to develop stronger inflammatory response during 
culture than diseased PCTS, as they shared more activated 
inflammation-related pathways. That could be due to the fact 
that diseased tissues, unlike healthy tissues, have already 
passed the initial inflammatory phase and are at the stage of 
fibrosis progression. Another example of pathology-specific 
differences is the culture-induced activation of p53 signal-
ling in diseased liver PCTS and not in healthy slices. It is 
well established that tumor suppressor p53 is highly sensi-
tive to DNA damage and cellular stress and regulates cell 
fate by directing damaged cells down the cell cycle arrest or 
apoptosis (Kastenhuber and Lowe 2017). Therefore, p53 sig-
nalling plays a central role in tumorigenesis and prognosis 
of hepatocellular carcinoma (Kunst et al. 2016). Consider-
ing that PCTS were prepared from cirrhotic livers that had 
considerable pre-existing DNA and cellular damage, culture 
induced activation of p53 pathway in these slices. In turn, 
diseased kidney and ileum PCTS actively involved pathways 
related to cholesterol biosynthesis, as opposed to healthy 
PCTS. We should note that cholesterol biosynthesis mainly 
takes place in the liver, but there were no significant changes 
in its regulation during culture in healthy or diseased liver 
PCTS.
Culturing process drives a common 
fibrosis‑associated state for healthy and diseased 
PCTS, while preserving diseased PCTS phenotype
Directly after slicing, healthy and diseased PCTS displayed 
pronounced differences in their transcriptomes that were 
driven solely by pre-existing pathology (Fig. 10: DEGs 
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A–B). Similar to this observation, we previously demon-
strated clear diseased phenotype of PCTS prepared from 
fibrotic kidneys: compared to healthy slices, fibrotic kid-
ney PCTS showed significantly higher baseline levels of 
COL1A1, FN1, IL1B, IL6, CXCL8 and TNF, as well as 
increased accumulation of interstitial collagen type I and 
alpha-SMA (unpublished data).
The obtained sequencing data allowed to identify the top 
pathology-driven transcripts differentially regulated between 
healthy and diseased PCTS. Here we took kidney PCTS as 
an example; however, an in-depth examination of transcrip-
tional differences prior to culture in kidney and other organ 
PCTS is not a focus of this discussion. Among 2016 genes 
differentially expressed between healthy and diseased kid-
ney PCTS (Fig. 14a), we found that 47 transcripts, encoding 
immunoglobulins (IGs), were highly upregulated in diseased 
kidney PCTS (with the highest fold increase of 45) (Fig. 14b 
and File S9). IGs are a critical part of the immune response, 
and increased mRNA levels of IGs might indicate active/
chronic inflammatory processes in diseased kidney PCTS. 
Highly upregulated CXCL13 (with 28-fold increase) fur-
ther argues for the uncontrolled aberrant inflammation in 
diseased renal tissue (Sato and Yanagita 2017). Gene UTS2, 
with 19-fold increase in diseased kidney PCTS compared to 
healthy PCTS, encodes urotensin II that has been shown to 
promote fibrosis, and its upregulated levels were observed 
in patients in the later stages of chronic kidney disease 
(CKD), particularly in individuals requiring dialysis (Eyre 
et al. 2019).
While liver and kidney PCTS showed pathology-driven 
differential expression of thousands of genes, healthy and 
diseased ileum PCTS failed to show differences in base-
line transcriptomes. This could be associated with the way 
human intestinal slices are prepared. Prior to slicing, the 
mucosa is stripped from all other layers, including submu-
cosa, muscularis externa and serosa, due to the technical 
difficulties they impose. In case of diseased ileum PCTS, 
the removal of deeper intestinal layers was detrimental to 
manifest their diseased phenotype. Intestinal fibrosis often 
follows the distribution of inflammation and is not neces-
sarily restricted to mucosa: in UC, the deposition of ECM 
occurs in mucosal and submucosal layers, whereas in CD, 
fibrosis can involve all intestinal wall layers (Rieder et al. 
2007; Speca 2012). Therefore, preparation of human intes-
tinal PCTS should be further optimized.
Remarkably, as both healthy and diseased PCTS dem-
onstrated extensive transcriptional changes during culture, 
after 48 h they showed minimal differences in acquired 
transcriptomes (counted in only tens/hundreds of DEGs) 
(Fig. 10: DEGs A’–B’). These observations indicate that 
during ex vivo culture, healthy and diseased human PCTS 
converge to a common condition, which is largely prompted 
by inflammatory and fibrogenic processes. This study 
provides a transcriptomic baseline for PCTS culture; how 
this resulting condition is predictive for human pathological 
processes is yet to be determined. Furthermore, the signa-
ture of pre-existing pathology remains in cultured slices and 
it may affect biological events other than gene regulation. 
For instance, underlying pathology may influence cell–cell 
interactions, production of ECM proteins, growth factors 
and cytokines. As we demonstrated, diseased PCTS had an 
increased production of cytokines and cytokine modula-
tors compared to healthy PCTS, emphasizing the value of 
diseased human tissue in fibrosis studies using the PCTS 
model. Importantly, the production of cytokines reflected 
the changes in their gene expression in PCTS during cul-
ture. Although protein synthesis and release are influenced 
by many cellular and molecular regulatory processes, the 
observed positive correlation between protein release and 
gene expression data argues for the fact that transcriptional 
changes detected by NGS are to some extent predictive for 
translational changes. However, it is important to continue 
investigating whether observed transcriptional changes 
in PCTS indeed translate to the protein level, by system-
atic analysis of the proteome. Given these points, PCTS 
obtained from patient diseased tissues might provide rel-
evant insights into fibrosis, therapeutic target validation and 
drug development.
Conclusions
In this study, we employed whole transcriptome sequencing 
to uncover the molecular processes that characterize PCTS 
culture. In Part I, we investigated species and organ differ-
ences in culture-associated responses in healthy murine and 
human PCTS. Part II of this study delineates the molecular 
processes in cultured human PCTS generated from diseased 
(fibrotic) tissues. Furthermore, we performed comparative 
analysis of transcriptomic profiles of human diseased and 
healthy control PCTS. In conclusion,
• We provided extensive characterization of the dynamic 
transcriptional changes in murine and human PCTS dur-
ing culture.
• We demonstrated that culture impacts all PCTS in a uni-
versal way by actively inducing inflammatory response 
and fibrosis-associated ECM remodelling. Despite the 
converging effects of culture, the underlying pathology in 
human diseased PCTS endures and influences biological 
processes such as cytokine release. This emphasizes the 
importance of using both healthy and diseased tissues in 
basic research and drug development.
• Although many pathways were shared, PCTS of different 
species and organs displayed an individualized response 
during culture.
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• Investigation of molecular processes that are similar in 
murine and human PCTS contributes to the understand-
ing of how mice fit into drug development of therapeutics 
for human diseases. However, how well the PCTS model 
reflects the in vivo situation is yet to be determined.
Taken together, our study largely contributes to our 
understanding of molecular mechanisms involved in PCTS 
culture and reinforces their use as an ex vivo fibrosis model, 
that is suitable for functional investigation of antifibrotic 
and anti-inflammatory therapies. This lays the foundation 
for future studies towards the assessment of predictivity of 
PCTS for human diseases and their validation as a preclini-
cal tool for drug development.
Acknowledgements The authors thank the abdominal transplanta-
tion surgeons of the Department of Hepato-Pancreato-Biliary Surgery 
and Liver Transplantation and surgeons of the Department of Urology 
(especially I.J. de Jong and A.M. Leliveld), University Medical Center 
Groningen for providing human tissue. We also would like to thank Dr. 
Tobias Hildebrandt and Werner Rust from the BI Genomics Lab for 
carrying out the RNA extraction and Next-Generation Sequencing of 
the PCTS. This work was kindly supported by ZonMW (The Nether-
lands Organization for Health Research and Development), Grant no. 
114025003.
Author contributions EB, EG, JFR and PO designed the study. PO 
acquired funding for this study. EB and EG prepared and collected 
mouse and human samples. KPdJ and HSH helped with human tissue 
procurement. ES and MZ carried out the sequencing and data analysis. 
EB, EG and MB interpreted the data. EB and EG wrote the manuscript 
with critical review from ES, MZ, AO, KPdJ, MS, PN, JFR and PO.
Compliance with ethical standards 
Conflict of interest Eric Simon, Matthias Zwick, Anouk Oldenburger, 
Marco Schlepütz, Paul Nicklin and Jörg F. Rippmann are full employ-
ees of Boehringer Ingelheim Pharma GmbH & Co. KG.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
Alsafadi HN, Staab-Weijnitz CA, Lehmann M et al (2017) An ex vivo 
model to induce early fibrosis-like changes in human precision-
cut lung slices. Am J Physiol Cell Mol Physiol 312:L896–L902. 
https ://doi.org/10.1152/ajplu ng.00084 .2017
Barksby HE, Milner JM, Patterson AM et al (2006) Matrix metallopro-
teinase 10 promotion of collagenolysis via procollagenase activa-
tion: implications for cartilage degradation in arthritis. Arthritis 
Rheum 54:3244–3253. https ://doi.org/10.1002/art.22167 
Bar-Or D, Rael LT, Thomas GW, Brody EN (2015) Inflammatory path-
ways in knee osteoarthritis: potential targets for treatment. Curr 
Rheumatol Rev 11:50–58. https ://doi.org/10.2174/15733 97111 
66615 05220 94131 
Bhattacharyya S, Midwood KS, Yin H, Varga J (2017) Toll-like recep-
tor-4 signaling drives persistent fibroblast activation and prevents 
fibrosis resolution in scleroderma. Adv Wound Care 6:356–369. 
https ://doi.org/10.1089/wound .2017.0732
Bigaeva E, Bomers JJM, Biel C et al (2019) Growth factors of stem 
cell niche extend the life-span of precision-cut intestinal slices 
in culture: a proof-of-concept study. Toxicol Vitro 59:312–321. 
https ://doi.org/10.1016/j.tiv.2019.05.024
Boztepe T, Gulec S (2018) Investigation of the influence of high 
glucose on molecular and genetic responses: an in vitro study 
using a human intestine model. Genes Nutr 13:11. https ://doi.
org/10.1186/s1226 3-018-0602-x
Bull DA, Reid BB, Connors RC et al (2000) Improved biochemical 
preservation of heart slices during cold storage. Int J Surg Inves-
tig 2:117–123
Chakraborty D, Šumová B, Mallano T et al (2017) Activation of 
STAT3 integrates common profibrotic pathways to promote 
fibroblast activation and tissue fibrosis. Nat Commun 8:1130. 
https ://doi.org/10.1038/s4146 7-017-01236 -6
Cheng R, Takahashi Y, Shen W et al (2013) Pathogenic role of dia-
betes-induced PPAR- down-regulation in microvascular dys-
function. Proc Natl Acad Sci 110:15401–15406. https ://doi.
org/10.1073/pnas.13072 11110 
Coulthard MG, Morgan M, Woodruff TM et al (2012) Eph/Ephrin sign-
aling in injury and inflammation. Am J Pathol 181:1493–1503. 
https ://doi.org/10.1016/j.ajpat h.2012.06.043
de Graaf IA, Groothuis GM, Olinga P (2007) Precision-cut tissue slices 
as a tool to predict metabolism of novel drugs. Expert Opin 
Drug Metab Toxicol 3:879–898. https ://doi.org/10.1517/17425 
255.3.6.879
de Graaf IAM, Olinga P, de Jager MH et al (2010) Preparation and 
incubation of precision-cut liver and intestinal slices for applica-
tion in drug metabolism and toxicity studies. Nat Protoc 5:1540–
1551. https ://doi.org/10.1038/nprot .2010.111
de Jong KP, Hoedemakers RMJ, Fidler V et al (2004) Portal and sys-
temic serum growth factor and acute-phase response after lapa-
rotomy or partial hepatectomy in patients with colorectal liver 
metastases: a prognostic role for C-reactive protein and hepato-
cyte growth factor. Scand J Gastroenterol 39:1141–1148. https 
://doi.org/10.1080/00365 52041 00096 09
de Kanter R, Tuin A, van de Kerkhof E et al (2005) A new technique 
for preparing precision-cut slices from small intestine and colon 
for drug biotransformation studies. J Pharmacol Toxicol Methods 
51:65–72. https ://doi.org/10.1016/j.vascn .2004.07.007
Dimitriadis G, Mitrou P, Lambadiari V et al (2011) Insulin effects in 
muscle and adipose tissue. Diabetes Res Clin Pract 93:S52–S59. 
https ://doi.org/10.1016/S0168 -8227(11)70014 -6
Domínguez-Avila J, González-Aguilar G, Alvarez-Parrilla E, de la 
Rosa L (2016) Modulation of PPAR expression and activity in 
response to polyphenolic compounds in high fat diets. Int J Mol 
Sci 17:1002. https ://doi.org/10.3390/ijms1 70710 02
El Hassani RA, Benfares N, Caillou B et al (2005) Dual oxidase2 is 
expressed all along the digestive tract. Am J Physiol Liver Phys-
iol 288:G933–G942. https ://doi.org/10.1152/ajpgi .00198 .2004
Elferink MGL, Olinga P, van Leeuwen EM et al (2011) Gene expres-
sion analysis of precision-cut human liver slices indicates stable 
expression of ADME-Tox related genes. Toxicol Appl Pharmacol 
253:57–69. https ://doi.org/10.1016/J.TAAP.2011.03.010
Eyre HJ, Speight T, Glazier JD et al (2019) Urotensin II in the devel-
opment and progression of chronic kidney disease following 5/6 
nephrectomy in the rat. Exp Physiol 104:421–433. https ://doi.
org/10.1113/EP087 366
Fink SP, Myeroff LL, Kariv R et al (2015) Induction of KIAA1199/
CEMIP is associated with colon cancer phenotype and poor 
3581Archives of Toxicology (2019) 93:3549–3583 
1 3
patient survival. Oncotarget 6:30500–30515. https ://doi.
org/10.18632 /oncot arget .5921
Fromenty B, Pessayre D (1995) Inhibition of mitochondrial beta-
oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 
67:101–154. https ://doi.org/10.1016/0163-7258(95)00012 -6
Geurts N, Martens E, Van Aelst I et al (2008) β-hematin interaction 
with the hemopexin domain of gelatinase B/MMP-9 provokes 
autocatalytic processing of the propeptide, thereby priming acti-
vation by MMP-3†. Biochemistry 47:2689–2699. https ://doi.
org/10.1021/bi702 260q
Gierut A, Perlman H, Pope RM (2010) Innate immunity and rheuma-
toid arthritis. Rheum Dis Clin North Am 36:271–296. https ://doi.
org/10.1016/j.rdc.2010.03.004
Grasberger H, Gao J, Nagao-Kitamoto H et al (2015) Increased expres-
sion of DUOX2 is an epithelial response to mucosal dysbiosis 
required for immune homeostasis in mouse intestine. Gastro-
enterology 149:1849–1859. https ://doi.org/10.1053/j.gastr 
o.2015.07.062
Haberman Y, Tickle TL, Dexheimer PJ et al (2014) Pediatric Crohn dis-
ease patients exhibit specific ileal transcriptome and microbiome 
signature. J Clin Invest 124:3617–3633. https ://doi.org/10.1172/
JCI75 436
Hafner C (2004) Differential gene expression of EPH receptors and 
ephrins in benign human tissues and cancers. Clin Chem 50:490–
499. https ://doi.org/10.1373/clinc hem.2003.02684 9
Heberle H, Meirelles GV, da Silva FR et al (2015) InteractiVenn: 
a web-based tool for the analysis of sets through Venn dia-
grams. BMC Bioinform 16:169. https ://doi.org/10.1186/s1285 
9-015-0611-3
Heimburger M, Larfars G, Bratt J (2000) Prednisolone inhibits 
cytokine-induced adhesive and cytotoxic interactions between 
endothelial cells and neutrophils in vitro. Clin Exp Immunol 
119:441–448. https ://doi.org/10.1046/j.1365-2249.2000.01165 .x
Hill CL, Hunter DJ, Niu J et al (2007) Synovitis detected on magnetic 
resonance imaging and its relation to pain and cartilage loss in 
knee osteoarthritis. Ann Rheum Dis 66:1599–1603. https ://doi.
org/10.1136/ard.2006.06747 0
Ho JK, Duclos RI, Hamilton JA (2002) Interactions of acyl carnitines 
with model membranes. J Lipid Res 43:1429–1439. https ://doi.
org/10.1194/jlr.M2001 37-JLR20 0
Hynes RO, Naba A (2012) Overview of the matrisome—an inventory 
of extracellular matrix constituents and functions. Cold Spring 
Harb Perspect Biol 4:a004903. https ://doi.org/10.1101/cshpe 
rspec t.a0049 03
Iswandana R, Pham BT, van Haaften WT et al (2016) Organ- and 
species-specific biological activity of rosmarinic acid. Toxicol 
Vitr 32:261–268. https ://doi.org/10.1016/j.tiv.2016.01.009
Kasper M, Seidel D, Knels L et al (2004) Early signs of lung fibrosis 
after in vitro treatment of rat lung slices with CdCl2 and TGF-
β1. Histochem Cell Biol 121:131–140. https ://doi.org/10.1007/
s0041 8-003-0612-6
Kastenhuber ER, Lowe SW (2017) Putting p53 in context. Cell 
170:1062–1078. https ://doi.org/10.1016/j.cell.2017.08.028
Katsoulieris EN, Drossopoulou GI, Kotsopoulou ES et al (2016) High 
glucose impairs insulin signaling in the glomerulus: an in vitro 
and ex vivo approach. PLoS One 11:e0158873. https ://doi.
org/10.1371/journ al.pone.01588 73
Kaverina I, Stradal TEB, Gimona M (2003) Podosome formation in 
cultured A7r5 vascular smooth muscle cells requires Arp2/3-
dependent de-novo actin polymerization at discrete micro-
domains. J Cell Sci 116:4915–4924. https ://doi.org/10.1242/
jcs.00818 
Kidani Y, Bensinger SJ (2014) LXR and PPAR as integrators of lipid 
homeostasis and immunity. J Immunol Rev 249:72–83. https ://
doi.org/10.1111/j.1600-065X.2012.01153 .x.LXR
Kim B, Jo J, Han J et al (2017) In silico re-identification of proper-
ties of drug target proteins. BMC Bioinform 18:248. https ://doi.
org/10.1186/s1285 9-017-1639-3
Krämer A, Green J, Pollard J, Tugendreich S (2014) Systems biol-
ogy causal analysis approaches in ingenuity pathway analysis. 
Bioinformatics 30:523–530. https ://doi.org/10.1093/bioin forma 
tics/btt70 3
Krebs HA (1933) Untersuchungen über den Stoffwechsel der Ami-
nosäuren im Tierkörper. Hoppe-Seyler Z 217:190–227
Kruithof E, Baker M, Bunn C (1995) Biological and clinical aspects 
of plasminogen activator inhibitor type 2. Blood 86:4006–4024
Krumdieck CL, dos Santos JE, Ho KJ (1980) A new instrument 
for the rapid preparation of tissue slices. Anal Biochem 
104:118–123
Kunst C, Haderer M, Heckel S et al (2016) The p53 family in hepa-
tocellular carcinoma. Transl Cancer Res 5:632–638. https ://doi.
org/10.21037 /11030 
Lee SH, Culberson C, Korneszczuk K, Clemens MG (2008) Differ-
ential mechanisms of hepatic vascular dysregulation with mild 
vs. moderate ischemia-reperfusion. Am J Physiol Liver Physiol 
294:G1219–G1226. https ://doi.org/10.1152/ajpgi .00527 .2007
Lee CG, Da Silva CA, Dela Cruz CS et al (2011) Role of chitin and 
chitinase/chitinase-like proteins in inflammation, tissue remod-
eling, and injury. Annu Rev Physiol 73:479–501. https ://doi.
org/10.1146/annur ev-physi ol-01211 0-14225 0
Lemoinne S, Cadoret A, El Mourabit H et al (2013) Origins and 
functions of liver myofibroblasts. Biochim Biophys Acta Mol 
Basis Dis 1832:948–954. https ://doi.org/10.1016/J.BBADI 
S.2013.02.019
Li M, de Graaf IAM, Groothuis GMM (2016) Precision-cut intestinal 
slices: alternative model for drug transport, metabolism, and tox-
icology research. Expert Opin Drug Metab Toxicol 12:175–190. 
https ://doi.org/10.1517/17425 255.2016.11258 82
Liu R-M, Gaston Pravia KA (2010) Oxidative stress and glutathione 
in TGF-β-mediated fibrogenesis. Free Radic Biol Med 48:1–15. 
https ://doi.org/10.1016/j.freer adbio med.2009.09.026
Lord CC, Thomas G, Brown JM (2013) Mammalian alpha beta hydro-
lase domain (ABHD) proteins: lipid metabolizing enzymes at 
the interface of cell signaling and energy metabolism. Biochim 
Biophys Acta 1831:792–802. https ://doi.org/10.1016/j.bbali 
p.2013.01.002
Luangmonkong T, Suriguga S, Bigaeva E et al (2017) Evaluating the 
antifibrotic potency of galunisertib in a human ex vivo model 
of liver fibrosis. Br J Pharmacol 174:3107–3117. https ://doi.
org/10.1111/bph.13945 
Luangmonkong T, Suriguga S, Adhyatmika A et al (2018) In vitro 
and ex vivo anti-fibrotic effects of LY2109761, a small molecule 
inhibitor against TGF-β. Toxicol Appl Pharmacol 355:127–137. 
https ://doi.org/10.1016/j.taap.2018.07.001
Lv W, Booz GW, Fan F et al (2018) Oxidative stress and renal fibro-
sis: recent insights for the development of novel therapeutic 
strategies. Front Physiol 9:105. https ://doi.org/10.3389/fphys 
.2018.00105 
Ma Q (2013) Role of Nrf2 in oxidative stress and toxicity. Annu Rev 
Pharmacol Toxicol 53:401–426. https ://doi.org/10.1146/annur 
ev-pharm tox-01111 2-14032 0
MacFie TS, Poulsom R, Parker A et al (2014) DUOX2 and DUOXA2 
form the predominant enzyme system capable of producing the 
reactive oxygen species  H2O2 in active ulcerative colitis and are 
modulated by 5-aminosalicylic acid. Inflamm Bowel Dis 20:514–
524. https ://doi.org/10.1097/01.MIB.00004 42012 .45038 .0e
Mann J, Chu DCK, Maxwell A et al (2010) MeCP2 controls an epi-
genetic pathway that promotes myofibroblast transdifferentia-
tion and fibrosis. Gastroenterology 138:705–714.e4. https ://doi.
org/10.1053/j.gastr o.2009.10.002
3582 Archives of Toxicology (2019) 93:3549–3583
1 3
Marcovina SM, Sirtori C, Peracino A et al (2013) Translating the basic 
knowledge of mitochondrial functions to metabolic therapy: role 
of l-carnitine. Transl Res 161:73–84. https ://doi.org/10.1016/j.
trsl.2012.10.006
Mathema VB, Koh Y-S, Thakuri BC, Sillanpää M (2012) Parthenolide, 
a sesquiterpene lactone, expresses multiple anti-cancer and anti-
inflammatory activities. Inflammation 35:560–565. https ://doi.
org/10.1007/s1075 3-011-9346-0
Medcalf RL, Stasinopoulos SJ (2005) The undecided ser-
pin. The ins and outs of plasminogen activator inhibi-
tor type 2. FEBS J 272:4858–4867. https ://doi.org/10.111
1/j.1742-4658.2005.04879 .x
Meng X, Nikolic-Paterson DJ, Lan HY (2016) TGF-β: the master 
regulator of fibrosis. Nat Rev Nephrol 12:325–338. https ://doi.
org/10.1038/nrnep h.2016.48
Metzker ML (2010) Sequencing technologies—the next generation. 
Nat Rev Genet 11:31–46. https ://doi.org/10.1038/nrg26 26
Mimche PN, Lee CM, Mimche SM et al (2018) EphB2 receptor 
tyrosine kinase promotes hepatic fibrogenesis in mice via acti-
vation of hepatic stellate cells. Sci Rep 8:2532. https ://doi.
org/10.1038/s4159 8-018-20926 -9
Murthy S, Born E, Mathur SN, Field FJ (2002) LXR/RXR activa-
tion enhances basolateral efflux of cholesterol in CaCo-2 cells. 
J Lipid Res 43:1054–1064. https ://doi.org/10.1194/jlr.M1003 
58-JLR20 0
Orsucci D, Mancuso M, Ienco EC et al (2011) Targeting mitochondrial 
dysfunction and neurodegeneration by means of coenzyme Q10 
and its analogues. Curr Med Chem 18:4053–4064. https ://doi.
org/10.2174/09298 67117 96957 257
Osman G, Rodriguez J, Chan SY et al (2018) PEGylated enhanced cell 
penetrating peptide nanoparticles for lung gene therapy. J Control 
Release 285:35–45. https ://doi.org/10.1016/j.jconr el.2018.07.001
Overall CM (2002) Molecular determinants of metalloproteinase sub-
strate specificity: matrix metalloproteinase substrate binding 
domains, modules, and exosites. Mol Biotechnol 22:051–086. 
https ://doi.org/10.1385/MB:22:1:051
Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases 
and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 
8:221–233. https ://doi.org/10.1038/nrm21 25
Parajuli N, Doppler W (2009) Precision-cut slice cultures of tumors 
from MMTV-neu mice for the study of the ex vivo response to 
cytokines and cytotoxic drugs. Vitr Cell Dev Biol Anim 45:442–
450. https ://doi.org/10.1007/s1162 6-009-9212-7
Parks WC, Wilson CL, López-Boado YS (2004) Matrix metallopro-
teinases as modulators of inflammation and innate immunity. 
Nat Rev Immunol 4:617–629. https ://doi.org/10.1038/nri14 18
Pham BT, van Haaften WT, Oosterhuis D et al (2015) Precision-cut 
rat, mouse, and human intestinal slices as novel models for the 
early-onset of intestinal fibrosis. Physiol Rep 3:e12323. https ://
doi.org/10.1414/phy2.12323 
Piccinini AM, Midwood KS (2010) DAMPening inflammation by 
modulating TLR signalling. Mediat Inflamm 2010:1–21. https 
://doi.org/10.1155/2010/67239 5
Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. 
Mol Aspects Med 21:49–98
Ratziu V, Harrison SA, Francque S et al (2016) Elafibranor, an agonist 
of the peroxisome proliferator– activated receptor– α and– δ, 
induces resolution of nonalcoholic steatohepatitis without fibro-
sis worsening. Gastroenterology 150:1147–1159.e5. https ://doi.
org/10.1053/j.gastr o.2016.01.038
Rehli M, Niller H-H, Ammon C et al (2003) Transcriptional regulation 
of CHI3L1, a marker gene for late stages of macrophage differen-
tiation. J Biol Chem 278:44058–44067. https ://doi.org/10.1074/
jbc.M3067 92200 
Remst DFG, Blaney Davidson EN, van der Kraan PM (2015) Unrav-
elling osteoarthritis-related synovial fibrosis: a step closer to 
solving joint stiffness. Rheumatology 54:1954–1963. https ://
doi.org/10.1093/rheum atolo gy/kev22 8
Rieder F, Brenmoehl J, Leeb S et al (2007) Wound healing and fibrosis 
in intestinal disease. Gut 56:130–139. https ://doi.org/10.1136/
gut.2006.09045 6
Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to 
organ injury and failure. N Engl J Med 372:1138–1149. https ://
doi.org/10.1056/NEJMr a1300 575
Roduit R, Morin J, Massé F et al (2000) Glucose down-regulates the 
expression of the peroxisome proliferator-activated receptor-α 
gene in the pancreatic β-cell. J Biol Chem 275:35799–35806. 
https ://doi.org/10.1074/jbc.M0060 01200 
Ruigrok MJR, Maggan N, Willaert D et al (2017) siRNA-mediated 
RNA interference in precision-cut tissue slices prepared from 
mouse lung and kidney. AAPS J 19:1855–1863. https ://doi.
org/10.1208/s1224 8-017-0136-y
Sack GH Jr (2018) Serum amyloid A—a review. Mol Med 24:46. https 
://doi.org/10.1186/s1002 0-018-0047-0
Sahin H, Wasmuth HE (2013) Chemokines in tissue fibrosis. Bio-
chim Biophys Acta Mol Basis Dis 1832:1041–1048. https ://doi.
org/10.1016/j.bbadi s.2012.11.004
Sato Y, Yanagita M (2017) Resident fibroblasts in the kidney: a major 
driver of fibrosis and inflammation. Inflamm Regen 37:17. https 
://doi.org/10.1186/s4123 2-017-0048-3
Schafer S, Viswanathan S, Widjaja AA et al (2017) IL-11 is a crucial 
determinant of cardiovascular fibrosis. Nature 552:110–115. 
https ://doi.org/10.1038/natur e2467 6
Schwertschlag US, Trepicchio WL, Dykstra KH et al (1999) Hemat-
opoietic, immunomodulatory and epithelial effects of interleu-
kin-11. Leukemia 13:1307–1315
Shay KP, Moreau RF, Smith EJ et al (2009) Alpha-lipoic acid as a 
dietary supplement: molecular mechanisms and therapeutic 
potential. Biochim Biophys Acta 1790:1149–1160. https ://doi.
org/10.1016/j.bbage n.2009.07.026
Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in 
inflammation and cancer. Annu Rev Immunol 28:367–388. https 
://doi.org/10.1146/annur ev.immun ol.02190 8.13260 3
Söllner JF, Leparc G, Hildebrandt T et al (2017) Data descriptor: an 
RNA-Seq atlas of gene expression in mouse and rat normal 
tissues background and summary. Nat Publ Gr. https ://doi.
org/10.1038/sdata .2017.185
Speca S (2012) Cellular and molecular mechanisms of intestinal fibro-
sis. World J Gastroenterol 18:3635. https ://doi.org/10.3748/wjg.
v18.i28.3635
Stribos EGD, Luangmonkong T, Leliveld AM et al (2016) Precision-
cut human kidney slices as a model to elucidate the process of 
renal fibrosis. Transl Res 170:8–16.e1. https ://doi.org/10.1016/j.
trsl.2015.11.007
Stribos EGD, Seelen MA, van Goor H et al (2017) Murine precision-
cut kidney slices as an ex vivo model to evaluate the role of trans-
forming growth factor-β1 signaling in the onset of renal fibrosis. 
Front Physiol 8:1026. https ://doi.org/10.3389/fphys .2017.01026 
’t Hart NA, van der Plaats A, Faber A et al (2005) Oxygenation during 
hypothermic rat liver preservation: an in vitro slice study to dem-
onstrate beneficial or toxic oxygenation effects. Liver Transplant 
11:1403–1411. https ://doi.org/10.1002/lt.20510 
Trapnell C, Hendrickson DG, Sauvageau M et al (2013) Differential 
analysis of gene regulation at transcript resolution with RNA-
seq. Nat Biotechnol 31:46–53. https ://doi.org/10.1038/nbt.2450
Tschumperlin DJ (2013) Fibroblasts and the ground they walk on. 
Physiology 28:380–390. https ://doi.org/10.1152/physi ol.00024 
.2013
Vatakuti S, Pennings JLA, Gore E et al (2016) Classification of chole-
static and necrotic hepatotoxicants using transcriptomics on 
human precision-cut liver slices. Chem Res Toxicol 29:342–351. 
https ://doi.org/10.1021/acs.chemr estox .5b004 91
3583Archives of Toxicology (2019) 93:3549–3583 
1 3
Wajner M, Amaral AU (2016) Mitochondrial dysfunction in fatty acid 
oxidation disorders: insights from human and animal studies. 
Biosci Rep 36:e00281. https ://doi.org/10.1042/BSR20 15024 0
Warburg O (1923) Versuche an überlebendem karzinomgewebe. Bio-
chem Z 142:317–333
Westra IM, Pham BT, Groothuis GMM, Olinga P (2013) Evaluation 
of fibrosis in precision-cut tissue slices. Xenobiotica 43:98–112. 
https ://doi.org/10.3109/00498 254.2012.72315 1
Westra IM, Oosterhuis D, Groothuis GMM, Olinga P (2014) Precision-
cut liver slices as a model for the early onset of liver fibrosis to 
test antifibrotic drugs. Toxicol Appl Pharmacol 274:328–338. 
https ://doi.org/10.1016/j.taap.2013.11.017
Westra IM, Mutsaers HAM, Luangmonkong T et al (2016) Human 
precision-cut liver slices as a model to test antifibrotic drugs in 
the early onset of liver fibrosis. Toxicol Vitro 35:77–85. https ://
doi.org/10.1016/j.tiv.2016.05.012
Wohlsen A, Uhlig S, Martin C (2001) Immediate allergic response in 
small airways. Am J Respir Crit Care Med 163:1462–1469. https 
://doi.org/10.1164/ajrcc m.163.6.20071 38
Wynn T (2004) Fibrotic disease and the TH1/TH2 paradigm. Nat Rev 
Immunol 4:583–594. https ://doi.org/10.1038/nri14 12
Wynn T (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 
214:199–210. https ://doi.org/10.1002/path.2277
Yadav NK, Shukla P, Omer A et al (2014) Next generation sequenc-
ing: potential and application in drug discovery. Sci World J 
2014:1–7. https ://doi.org/10.1155/2014/80243 7
Yamaguchi H, Lorenz M, Kempiak S et al (2005) Molecular mecha-
nisms of invadopodium formation. J Cell Biol 168:441–452. 
https ://doi.org/10.1083/jcb.20040 7076
Yu R, Jiang S, Tao Y et al (2019) Inhibition of HMGB1 improves 
necrotizing enterocolitis by inhibiting NLRP3 via TLR4 and 
NF-κB signaling pathways. J Cell Physiol 234:13431–13438. 
https ://doi.org/10.1002/jcp.28022 
Zeisberg M, Kalluri R (2013) Cellular mechanisms of tissue fibrosis. 
1. common and organ-specific mechanisms associated with tis-
sue fibrosis. Am J Physiol Physiol 304:C216–C225. https ://doi.
org/10.1152/ajpce ll.00328 .2012
Zhang Q, Raoof M, Chen Y et  al (2010) Circulating mitochon-
drial DAMPs cause inflammatory responses to injury. Nature 
464:104–107. https ://doi.org/10.1038/natur e0878 0
Zhong T, Tang J, Liu Y et  al (2009) High mobility group box-1 
stimulates proinflammatory cytokine production in endothe-
lial cells via MAP kinases. Nan Fang Yi Ke Da Xue Xue Bao 
29:1517–1520
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Emilia Bigaeva1  · Emilia Gore1  · Eric Simon2  · Matthias Zwick2 · Anouk Oldenburger3  · Koert P. de Jong4 · 
Hendrik S. Hofker5 · Marco Schlepütz6 · Paul Nicklin7 · Miriam Boersema1  · Jörg F. Rippmann3  · Peter Olinga1 
1 Department of Pharmaceutical Technology 
and Biopharmacy, University of Groningen, Antonius 
Deusinglaan 1, Groningen 9713AV, The Netherlands
2 Computational Biology, Boehringer Ingelheim 
Pharma GmbH & Co. KG, Birkendorfer Str. 65, 
88397 Biberach an der Riss, Germany
3 Cardiometabolic Disease Research, Boehringer Ingelheim 
Pharma GmbH & Co. KG, Birkendorfer Str. 65, 
88397 Biberach an der Riss, Germany
4 Department of Hepato-Pancreato-Biliary Surgery and Liver 
Transplantation, University Medical Center Groningen, 
University of Groningen, Hanzeplein 1, 9713 GZ Groningen, 
The Netherlands
5 Department of Surgery, University Medical Center 
Groningen, University of Groningen, Hanzeplein 1, 
9713 GZ Groningen, The Netherlands
6 Respiratory Diseases, Boehringer Ingelheim Pharma GmbH 
& Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, 
Germany
7 Research Beyond Borders, Boehringer Ingelheim 
Pharma GmbH & Co. KG, Birkendorfer Str. 65, 
88397 Biberach an der Riss, Germany
